<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-id journal-id-type="coden">jmcmar</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7707623</article-id><article-id pub-id-type="pmid">33180487</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.0c01482</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Multipronged
Approach Establishes Covalent Modification
of &#x003b2;-Tubulin as the Mode of Action of Benzamide Anti-cancer
Toxins</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Povedano</surname><given-names>Juan Manuel</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="notes1" ref-type="notes">&#x02207;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Rallabandi</surname><given-names>Rameshu</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="notes1" ref-type="notes">&#x02207;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Bai</surname><given-names>Xin</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Ye</surname><given-names>Xuecheng</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Liou</surname><given-names>Joel</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Chen</surname><given-names>Hong</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Kim</surname><given-names>Jiwoong</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Xie</surname><given-names>Yang</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Posner</surname><given-names>Bruce</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Rice</surname><given-names>Luke</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath11"><name><surname>De Brabander</surname><given-names>Jef K.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath12"><name><surname>McFadden</surname><given-names>David G.</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Internal Medicine, Division of Endocrinology, <institution>University of Texas Southwestern Medical Center</institution>, Dallas, Texas 75390, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Biochemistry, <institution>University of Texas Southwestern
Medical Center</institution>, Dallas, Texas 75390, <country>United States</country></aff><aff id="aff3"><label>&#x000a7;</label>Harold
C. Simmons Comprehensive Cancer Center, <institution>University of Texas Southwestern Medical Center</institution>, Dallas, Texas 75390, <country>United States</country></aff><aff id="aff4"><label>&#x02225;</label>Program
in Molecular Medicine, <institution>University of Texas
Southwestern Medical Center</institution>, Dallas, Texas 75390, <country>United States</country></aff><aff id="aff5"><label>&#x022a5;</label>Quantitative
Biomedical Research Center, Department of Population and Data Sciences, <institution>University of Texas Southwestern Medical Center</institution>, Dallas, Texas 75390, <country>United States</country></aff><aff id="aff6"><label>#</label>Department
of Biophysics, <institution>University of Texas Southwestern
Medical Center</institution>, Dallas, Texas 75390, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>jef.debrabander@utsouthwestern.edu</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>david.mcfadden@utsouthwestern.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="ppub"><day>25</day><month>11</month><year>2020</year></pub-date><volume>63</volume><issue>22</issue><fpage>14054</fpage><lpage>14066</lpage><history><date date-type="received"><day>11</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 American Chemical
Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license><license-p>This is an open access article published under an ACS AuthorChoice <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_0009" id="ab-tgr1"/></p><p>A phenotypic
high-throughput screen identified a benzamide small
molecule with activity against small cell lung cancer cells. A &#x0201c;clickable&#x0201d;
benzamide probe was designed that irreversibly bound a single 50 kDa
cellular protein, identified by mass spectrometry as &#x003b2;-tubulin.
Moreover, the anti-cancer potency of a series of benzamide analogs
strongly correlated with probe competition, indicating that &#x003b2;-tubulin
was the functional target. Additional evidence suggested that benzamides
covalently modified Cys239 within the colchicine binding site. Consistent
with this mechanism, benzamides impaired growth of microtubules formed
with &#x003b2;-tubulin harboring Cys239, but not &#x003b2;<sub>3</sub> tubulin encoding Ser239. We therefore designed an aldehyde-containing
analog capable of trapping Ser239 in &#x003b2;<sub>3</sub> tubulin,
presumably as a hemiacetal. Using a forward genetics strategy, we
identified benzamide-resistant cell lines harboring a Thr238Ala mutation
in &#x003b2;-tubulin sufficient to induce compound resistance. The disclosed
chemical probes are useful to identify other colchicine site binders,
a frequent target of structurally diverse small molecules.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm0c01482</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm0c01482</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>The identification
and development of new cancer therapies remain
a challenge. Target-based screens have proven effective at identifying
small molecule inhibitors for oncogenic kinases that are recurrently
mutated in many cancers. However, for tumors without mutations in
these kinases, phenotypic screens offer a powerful complementary approach
in which small molecules with anti-cancer activity can be identified
in high-throughput format. The establishment of preliminary structure&#x02013;activity
relationships around these initial HTS hits is essential to facilitate
the development of chemical probes suitable for target identification.
If the biological target lends itself to a more translational evaluation,
then more sophisticated medicinal chemistry optimization is useful
for initial in vivo proof of concept studies in animal models of human
cancer.</p><p>Small cell lung cancer (SCLC) is an aggressive neuroendocrine
(NE)
malignancy, and a diagnosis of SCLC portends poor survival. Treatments
for SCLC have remained largely unchanged, and cytotoxic chemotherapies
remain the foundation of therapy for SCLC. The failure to improve
outcomes in SCLC stems in part from a lack of recurrent mutations
that encode chemically tractable proteins. We leveraged genetically
defined cancer cell lines derived from a mouse model of SCLC to facilitate
phenotypic screening for anti-cancer small molecules with activity
against SCLC and other NE tumors.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref4">4</xref></sup> Here, we report the identification of a
series of benzamides that exhibit anti-cancer activity to murine and
human SCLC cell lines. We utilize a combination of medicinal chemistry,
probe reagent development, forward genetics, and <italic>in vitro</italic> assays of microtubule dynamics to demonstrate that these small molecules
covalently modify &#x003b2;-tubulin via nucleophilic aromatic substitution.</p></sec><sec id="sec2"><title>Results
and Discussion</title><sec id="sec2.1"><title>Identification and Structure&#x02013;Activity
Relationship Studies
(SAR) of Benzamide SCLC Toxins</title><p>We identified a benzamide-phenyl
piperazine from a phenotypic high-throughput chemical screen aimed
at identifying small molecules with selective anti-cancer activity
against a panel of mouse and human SCLC cell lines. Benzamide <bold>1</bold> was active against three independent murine SCLC (mSCLC)
cell lines with an average EC<sub>50</sub> of 3.21 &#x000b1; 0.6 &#x003bc;M
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A,B). Moreover,
three human SCLC cell lines, H889, H2107, and H128, exhibited sensitivity,
suggesting conserved expression of the protein target of compound <bold>1</bold> in mouse and human cells (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">Supporting Information</ext-link><xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). A literature search identified a previous study reporting
that benzamide <bold>1</bold> was toxic to yeast cells through inhibition
of Sec14, a protein essential for membrane trafficking in the Golgi-endosomal
system.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> However, less than 30% amino acid
sequence conservation between yeast and mammalian Sec14 orthologs
raised the possibility that compound <bold>1</bold> induced SCLC cell
death through Sec14-independent mechanisms. We therefore initiated
an unbiased medicinal chemistry and forward genetics approach to identify
the target of benzamide <bold>1</bold>.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Structure&#x02013;activity
relationships of 4-chloro-3-nitrobenzamide
SCLC toxins. (A) Table with half-maximal inhibitory concentrations
(IC<sub>50</sub>) for benzamide analogs <bold>1</bold>&#x02013;<bold>15</bold> against murine SCLC cell line 319N1. Standard error is
indicated between brackets and is based on <italic>n</italic> = 2
technical replicates. (B) Dose&#x02013;response curves of compound <bold>1</bold> against three murine SCLC cell lines. (C) Dose&#x02013;response
curves of compounds <bold>1</bold>, <bold>10</bold>, and <bold>15</bold> against murine SCLC cell line 319N1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_0002" id="gr1" position="float"/></fig><p>We synthesized analogs of compound <bold>1</bold> to understand
structure&#x02013;activity relationships that would enable the development
of chemical probes for target identification. Systematic modification
to the phenyl piperazine ring revealed that substitutions at the R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> positions impacted toxicity
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A,C). The
chlorine substituent at position R<sup>1</sup> slightly improved potency
(<bold>2</bold>), whereas <italic>ortho</italic>-fluorine analog <bold>12</bold> was 2-fold less active than parent benzamide <bold>1</bold>. At the R<sup>2</sup> position, bromine, chlorine, and cyano groups
improved activity &#x0223c;5 to 7-fold (analogs <bold>6</bold>&#x02013;<bold>8</bold>), whereas <italic>meta</italic>-methyl and methoxy-substituted
analogs <bold>3</bold> and <bold>4</bold> were only &#x0223c;3-fold
more potent. Of the various 2,5-disubstituted combinations tested,
analog <bold>10</bold> (R<sup>1</sup> = Me and R<sup>2</sup> = Cl)
was the most potent benzamide with an EC<sub>50</sub> of 182 nM. In
contrast, modifications at the <italic>para</italic>-position (R<sup>3</sup> = F, Me, and MeO; analogs <bold>11</bold> and <bold>13</bold>&#x02013;<bold>15</bold>) significantly impacted the cytotoxic activity
within this series.</p><p>Initial experiments had shown that the 4-chloro-3-nitro
substitution
pattern was an essential feature required for the ability of the benzamides
to affect growth of the mSCLC cell line 319N1. For example, removing
either of these substituents from the benzamide ring resulted in complete
eradication of antiproliferative activity (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Table 1 and SI Figure 2</ext-link>, compounds <bold>28</bold> and <bold>29</bold>). As shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A,B, we designed and evaluated several other analogs
with alternate chloro/nitro substitution patterns (<bold>16</bold>&#x02013;<bold>19</bold>), but all resulted in significantly less
active benzamides when compared to 4-chloro-3-nitrobenzamide analog <bold>10</bold> (EC<sub>50</sub> = 182 nM). These initial results, with
the position of the chlorine substituent <italic>ortho</italic> and <italic>para</italic> to the mesomeric electron-withdrawing nitro and benzamide
carbonyl in the most active analog <bold>10</bold>, raised the possibility
that nucleophilic aromatic substitution (S<sub>N</sub>Ar) was important
for the activity of these molecules. According to this model, we hypothesized
that a nucleophilic amino acid side chain within a benzamide binding
protein would displace the 4-chloro substituent via S<sub>N</sub>Ar,
resulting in a covalent bond to the target protein (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>D).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Structure&#x02013;activity
relationships of the 4-chloro-3-nitrobenzamide
warhead reveal that benzamides bind covalently to p50 via aromatic
nucleophilic substitution. (A) Table with half-maximal inhibitory
concentrations (IC<sub>50</sub>) for benzamide analogs against murine
SCLC line 319N1. Standard error is indicated between brackets and
is based on <italic>n</italic> = 2 technical replicates. (B and C)
Dose&#x02013;response curves for analogs <bold>10</bold> and <bold>16</bold>&#x02013;<bold>23</bold> against murine SCLC cell line 319N1.
(D) Model for potential covalent cross-linking of the 4-chloro-3-nitrobenzamide
warhead with binding protein via nucleophilic aromatic substitution.
(E) Benzamide alkyne probe reagents <bold>24</bold> and <bold>25</bold> with half-maximal inhibitory concentrations (IC<sub>50</sub>) against
murine SCLC line 319N1. Standard error is indicated between brackets
and is based on <italic>n</italic> = 2 technical replicates. (F) SDS-PAGE
gels of fluorescent azide dye-treated cell lysates obtained from 518T2
murine SCLC cells incubated with increasing concentrations of analogs <bold>24</bold> and <bold>25</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_0003" id="gr2" position="float"/></fig><p>To further evaluate this model, we generated analogs in which the
chlorine leaving group was replaced with other leaving groups including
fluorine, bromine, or iodine (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A,C). The activity of <bold>20</bold> (EC<sub>50</sub> = 818 nM), <bold>10</bold> (EC<sub>50</sub> = 182 nM), <bold>21</bold> (EC<sub>50</sub> = 55 nM), and <bold>22</bold> (EC<sub>50</sub> =
51 nM) positively correlated with the leaving group potential and
the size of the halide substituent at position 4. Interestingly, analog <bold>23</bold> bearing 4-OCF<sub>3</sub> was the most potent benzamide
tested (EC<sub>50</sub> = 20 nM).<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> The
impact of all these benzamide ring modifications was consistent with
a nucleophilic aromatic substitution mediating a covalent compound&#x02013;protein
interaction.</p></sec><sec id="sec2.2"><title>Benzamides Bind Covalently to a Protein p50,
Identified as &#x003b2;-Tubulin</title><p>We developed alkyne-modified
chemical probes to visualize potential
covalent small molecule protein complexes by SDS-PAGE via a copper-mediated
click reaction with a fluorescent azide dye for in-gel detection.<sup><xref ref-type="bibr" rid="ref7">7</xref>&#x02212;<xref ref-type="bibr" rid="ref9">9</xref></sup> Based on the SAR described in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>, we decided to introduce the alkyne &#x0201c;click&#x0201d;
handle in the <italic>meta</italic>-position of the piperazinophenyl
ring as a phenolic propargyl ether. Alkyne <bold>24</bold> harbored
the benzamide S<sub>N</sub>Ar warhead, whereas the corresponding alkyne
analog <bold>25</bold> was substituted with a methyl group of similar
van der Waals radius to chlorine but would not be expected to covalently
bind to the target protein (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>E). Consistent with this, methyl-substituted benzamide <bold>25</bold> was 10-fold less active compared to <bold>24</bold> (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>E).</p><p>To visualize
potential covalently modified proteins, murine SCLC cells were incubated
with varying concentrations of either <bold>24</bold> or <bold>25</bold> (from 50 nM to 50 &#x003bc;M). Protein lysates were then subjected
to the copper-mediated click reaction using a fluorescent azide dye
(Alexa Fluor 532), and protein-probe complexes were visualized using
an SDS-PAGE gel. A single dominant 50 kDa protein (hereafter referred
as p50) was covalently modified by S<sub>N</sub>Ar reactive probe <bold>24</bold>, a band which was not observed in lysates incubated with <bold>25</bold> (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>F and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Figure 3</ext-link>).</p><p>Although the
above experiments clearly demonstrated that the benzamide
probe with an active S<sub>N</sub>Ar warhead (<bold>24</bold>) was
capable of forming an irreversible complex with p50, it remained to
be determined whether this interaction was relevant to the anti-cancer
activity of these compounds. To address this question in a quantitative
fashion, we selected nine benzamide analogs that varied in potency
between 51 nM and 4.36 &#x003bc;M in the cell-based phenotypic assay
(cytotoxicity against mSCLC cell line 319N1) for a cell-based competition
experiment with the clickable alkyne probe <bold>24</bold> in the
probe-binding assay (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Figure 4</ext-link>). We identified
a positive correlation between the cellular toxicity (IC<sub>50</sub>) of these nine analogs (see <xref rid="fig1" ref-type="fig">Figures <xref rid="fig1" ref-type="fig">1</xref></xref>A and <xref rid="fig2" ref-type="fig">2</xref>A) and their respective
ability to displace alkyne probe <bold>24</bold> (EC<sub>50</sub>)
with an <italic>R</italic><sup>2</sup> value of 0.8895 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). These results were consistent
with p50 binding being responsible for the anti-cancer activity of
this series of benzamide analogs.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Binding of benzamides to the &#x003b2;-tubulin
colchicine site is
responsible for toxicity in SCLC cells. (A) SDS-PAGE gels of fluorescent
azide dye-treated cell lysates obtained from 518T2 murine SCLC cells
incubated with alkyne probe <bold>24</bold> (5 &#x003bc;M) after pre-treatment
with increasing concentrations of compounds <bold>1</bold>&#x02013;<bold>4</bold>, <bold>6</bold>, <bold>10</bold>, and <bold>20&#x02013;22</bold>. (B) Correlation among nine benzamide analogs for toxicity (IC<sub>50</sub>) and p50 binding (EC<sub>50</sub>). (C) Silver-stained SDS-PAGE
gel of pull-down samples treated with probe <bold>24</bold> or probe <bold>25</bold>. (D) Fold change of &#x003b2;<sub>5</sub> tubulin peptide
abundance in sample <bold>24</bold> normalized to sample <bold>25</bold>. (E) SDS-PAGE gels of fluorescent azide dye-treated cell lysates
obtained from 518T2 murine SCLC cells incubated with alkyne probe <bold>24</bold> (5 &#x003bc;M) after pre-treatment with increasing concentrations
of colchicine or vincristine.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_0004" id="gr3" position="float"/></fig><p>To enable identification of p50 using chemical probe&#x02013;protein
precipitation and mass spectrometry-based proteomics, the cross-linking
experiment was repeated on a larger scale. After incubating cells
with covalent alkyne probe <bold>24</bold> or with non-covalent probe <bold>25</bold>, lysates were prepared and clicked to a biotin azide (instead
of a fluorescent azide). The resulting biotin&#x02013;protein&#x02013;probe
complexes were precipitated with streptavidin beads followed by boiling
the beads. Proteins in the eluate were analyzed by SDS-PAGE and visualized
using silver staining, confirming that p50 was pulled down in the
sample treated with covalent probe <bold>24</bold> but not in the
sample with compound <bold>25</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>C). Shotgun LC&#x02013;MS/MS analysis identified
&#x003b2;-tubulin as the only protein enriched in the probe <bold>24</bold> treated sample (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Table 2</ext-link>), of which
&#x003b2;-tubulin isoform 5 (Tubb5; &#x003b2;<sub>5</sub> tubulin) was
the most enriched (12.95-fold) of the various isoforms.</p></sec><sec id="sec2.3"><title>Benzamides
Bind &#x003b2;-Tubulin in the Colchicine Binding Pocket
and Alter Microtubule Dynamics</title><p>Notably, when focusing on
the peptide counts for Tubb5 (&#x003b2;<sub>5</sub> tubulin), we found
that there was one single peptide (aa217-241) that was depleted from
the probe-only treated sample (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>D). We hypothesized that this peptide was depleted
from the MS dataset due to a mass shift resulting from a covalent
modification with the probe. The 217-241 peptide contained a single
cysteine, raising the possibility that this residue acted as the nucleophile
in the S<sub>N</sub>Ar reaction with the probe. There have been at
least two other small molecules reported to covalently modify &#x003b2;-tubulin
at Cys239. T0070907 was a compound initially identified as an inhibitor
of PPAR<bold>&#x003b3;</bold> via covalent modification of Cys313.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Subsequently, T0070907 was shown to also induce
tubulin degradation<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> followed by a report by Yang
et al. showing covalent modification of Cys239 of &#x003b2;-tubulin
via displacement of the chlorine <italic>para</italic> to the nitro
group in the 2-Cl-5-nitrobenzamide moiety of T0070907.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Another compound, T138067 was also shown to
bind covalently to &#x003b2;-tubulin through Cys239 by displacement
of the <italic>para</italic>-fluorine in the pentafluorophenylsulfonamide
warhead of T138067.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup></p><p>Colchicine is a natural
product that binds &#x003b2;-tubulin in a pocket located near the &#x003b1;&#x003b2;-tubulin
heterodimer interface. Cys239 lies within the colchicine binding pocket
of &#x003b2;-tubulin and has been shown to be important for colchicine
activity.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Because our data suggested
that benzamides interact with Cys239 within the colchicine binding
pocket, we performed a competition experiment between covalent benzamide
probe <bold>24</bold> and colchicine. As depicted in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>E, colchicine was able to displace
binding of alkyne probe <bold>24</bold> (5 &#x003bc;M) to p50 in a dose-dependent
manner with an EC<sub>50</sub> of 2.8 &#x003bc;M. Also, no such probe
competition was observed with vincristine, a microtubule-destabilizing
agent that acts at a site distinct from the colchicine site (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>E). This data provided
additional evidence that benzamides bound &#x003b2;-tubulin within the
colchicine binding pocket.</p><p>Colchicine and other drugs that target
&#x003b2;-tubulin impair microtubule
dynamics and cause cell cycle arrest at the G<sub>2</sub>/M transition
due to the impairment of chromosome segregation during mitosis.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> As expected, cell cycle analysis indicated that
mSCLC cells treated with 300 nM colchicine or benzamide analog <bold>21</bold> (IC<sub>50</sub> = 69 nM) for 24 h induced G<sub>2</sub>/M cell cycle arrest (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Benzamide analog <bold>21</bold> inhibits microtubule growth and
induces G2/M cell cycle arrest. (A) Cell cycle analysis by flow cytometry
of 518T2 cells treated with DMSO, analog <bold>21</bold> (300 nM),
or colchicine (300 nM) for 24 h. (B) Quantification of the growth
rate of microtubules using brain tubulin from samples treated with
DMSO (33 microtubules quantified) and samples treated with analog <bold>21</bold> (21 microtubules quantified); <italic>n</italic> = 1 trial.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_0005" id="gr4" position="float"/></fig><p>Microtubules are dynamic structures in the cell
that undergo phases
of growth and shrinkage in a phenomenon called dynamic instability.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Drugs that bind the colchicine binding pocket
of &#x003b2;-tubulin alter these dynamics and destabilize microtubule
fibers.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> We therefore performed <italic>in vitro</italic> microtubule formation assays to assess the impact
of benzamide analog <bold>21</bold> on microtubule dynamics. Compared
to control, the growth of bovine brain microtubules was reduced by
approximately 80% in the presence of analog <bold>21</bold> even at
10:1 (tubulin/compound) ratio (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Figure 5A</ext-link>).</p></sec><sec id="sec2.4"><title>Targeting
the &#x003b2;<sub>3</sub> Tubulin Isoform with Aldehyde-Modified
Benzamides</title><p>A common mechanism of resistance to taxanes, the
most commonly used microtubule-targeting agent for cancer therapy,
is the overexpression of &#x003b2;<sub>3</sub> tubulin (encoded by TUBB3)
in which Arg277 replaces Ser277 in the M loop, greatly reducing the
binding of taxane agents.<sup><xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup> Therefore, agents that
target a site distinct from where taxanes bind could have translational
potential. Given that the benzamides described herein target the colchicine
site, we considered whether these might be active against &#x003b2;<sub>3</sub> tubulin overexpressing cancers.<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> However, the isoform switch to &#x003b2;<sub>3</sub> tubulin indirectly
impacts the colchicine binding pocket because TUBB3 encodes serine
at position 239, rather than cysteine. Given that benzamides covalently
modified &#x003b2;-tubulin potentially via Cys239 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>D), their binding affinity
for the Ser239 containing &#x003b2;<sub>3</sub> isoform could be dramatically
impaired. Indeed, our proteomic datasets indicated that &#x003b2;<sub>3</sub> tubulin was enriched only 3-fold compared to the average
9.2-fold enrichment for the other isoforms of &#x003b2;-tubulin (&#x003b2;<sub>2A</sub>, &#x003b2;<sub>2B</sub>, &#x003b2;<sub>4A</sub>, &#x003b2;<sub>4B</sub>, and &#x003b2;<sub>5</sub>), which harbor a cysteine at position
239 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Table 2</ext-link>). Consistent with this
observation, benzamide analog <bold>21</bold> (up to 10 &#x003bc;M)
failed to impair the <italic>in vitro</italic> microtubule growth
rate of tubulin preparations using human recombinant &#x003b2;<sub>3</sub> tubulin (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Figure 5B</ext-link>),<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> whereas this same compound (at 1 &#x003bc;M) dramatically
affected the growth of brain tubulin containing primarily the Cys239
containing &#x003b2;-tubulin isoforms (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Formyl-substituted benzamide analog <bold>26</bold> enables the
inhibition of the Ser239-containing &#x003b2;<sub>3</sub> tubulin isoform.
(A) Model for hemiacetal formation of benzaldehyde analog <bold>26</bold> with serine or cysteine residues. (B) Quantification of the growth
rate of &#x003b2;<sub>3</sub> tubulin microtubules treated with DMSO
(<italic>n</italic> = 131 microtubules quantified over three trials)
or analog <bold>21</bold> (<italic>n</italic> = 126 microtubules quantified
over three trials). (C) Dose&#x02013;response curve of compound <bold>26</bold> in murine SCLC cell line 319N1. (D) Quantification of the
growth rate of microtubules using &#x003b2;<sub>3</sub> tubulin treated
with DMSO (<italic>n</italic> = 107 microtubules quantified over two
trials) or analog <bold>26</bold> at 1 &#x003bc;M (<italic>n</italic> = 119 microtubules quantified over two trials), 5 &#x003bc;M (<italic>n</italic> = 102 microtubules quantified over two trials), and 10
&#x003bc;M (<italic>n</italic> = 71 microtubules quantified over two
trials). (E) Quantification of the growth rate of microtubules using
brain tubulin from samples treated with DMSO (<italic>n</italic> =
32 microtubules quantified over one trial) or analog <bold>26</bold> (<italic>n</italic> = 36 microtubules quantified over one trial).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_0006" id="gr5" position="float"/></fig><p>We therefore set out to design an analog that would
engage serine
239 in hemiacetal formation with an appropriately placed aldehyde.
Importantly, it was anticipated that such an analog would retain the
capacity to capture Cys239 isoforms in the form of a hemithioacetal
instead of via S<sub>N</sub>Ar (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A). Gratifyingly, replacing the halide substituent
in the benzamide ring with a formyl group led to analog <bold>26</bold> that retained potent anti-cancer activity against 319N1 mSCLC cells
(EC<sub>50</sub> = 127 nM) (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>C). Consistent with our hypothesis, benzaldehyde <bold>26</bold> dose-dependently altered the dynamics of microtubules composed
exclusively of &#x003b2;<sub>3</sub> tubulin in a dose-dependent manner
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>D). Microtubule
growth rate was reduced from 0.83 &#x003bc;m/min in the DMSO control
to 0.67 &#x003bc;m/min with analog <bold>26</bold> (10:1 ratio &#x003b2;<sub>3</sub> tubulin/<bold>27</bold>). Further growth rate reduction was
achieved at higher analog <bold>26</bold> concentrations, reaching
0.31 &#x003bc;m/min at 10 &#x003bc;M (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>D and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Figure 5B</ext-link>). Importantly, benzaldehyde <bold>26</bold> also potently reduced
the growth of microtubules in preparations of bovine brain tubulin,
which is composed primarily of Cys239-containing &#x003b2;-tubulin isoforms
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>E and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Figure 5C</ext-link>). In conclusion, aldehyde analogs
such as <bold>26</bold> target both Cys239 and Ser239 isoforms, presumably
via hemiacetal/hemithioacetal formation, which lays out a potential
chemical strategy to target cancers that acquire resistance through
&#x003b2;<sub>3</sub> tubulin overexpression.</p></sec><sec id="sec2.5"><title>Competition with Benzamide
Probe <bold>24</bold> and Forward
Genetics Identify Another HTS Hit That Binds &#x003b2;-Tubulin at the
Colchicine Binding Site</title><p>Given that microtubules are frequently
targeted by small molecules, by design or unintended,<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref></sup> we contemplated that benzamide
probe <bold>24</bold> might be useful to identify other toxins that
act through binding at the &#x003b2;-tubulin colchicine site. When we
examined our mSCLC HTS hit list, a chloronitrobenzenesulfonamidobenzofuran
(<bold>27</bold>, IC<sub>50</sub> = 2.8 &#x003bc;M, <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>A,B) was flagged as containing
structural features essential for nucleophilic aromatic substitution.
As shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>C, sulfonamide <bold>27</bold> displaced probe <bold>24</bold> from
p50 in a dose-responsive manner. This result is consistent with the
notion that microtubules are the mechanistic target of compound <bold>27</bold>, presumably via covalent capture of Cys239 &#x003b2;-tubulin
isoforms.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p><italic>Tubb5<sup>T238A</sup></italic> compound-resistant allele
identified by forward genetics is sufficient to confer benzamide resistance
in murine SCLC cells. (A) Structure of compound <bold>27</bold>. (B)
Dose&#x02013;response curve of compounds <bold>1</bold> and <bold>27</bold> against a murine SCLC cell line 319N1. Standard error is indicated
between brackets and is based on <italic>n</italic> = 2 technical
replicates. (C) SDS-PAGE gels of fluorescent azide dye-treated cell
lysates obtained from 518T2 murine SCLC cells incubated with alkyne
probe <bold>24</bold> (5 &#x003bc;M) after pre-treatment with increasing
concentrations of compound <bold>27</bold>. (D and E) Dose&#x02013;response
curves of compounds <bold>27</bold> and <bold>10</bold> in parental <italic>Msh2</italic>-deficient 319N1-M2KO cell line and resistant clones
A&#x02013;E. (F) Table with half-maximal inhibitory concentrations
(IC<sub>50</sub>) for benzamide analogs <bold>10</bold> and <bold>27</bold> against the parental 319N1-M2KO cell line and five resistant
clones A&#x02013;E. (G) <italic>Tubb5</italic> is one of the only 22
genes recurrently mutated in all five resistant clones. (H) Crystal
violet staining of murine SCLC (518T2) cells edited in <italic>Tubb5</italic> harboring the T238A mutation (top). Binary images from crystal violet
images enable clearer representation of alive cells in the <italic>Tubb5</italic> (T238A) sample (bottom). (I) Dose&#x02013;response
curves of analog <bold>21</bold> in 518T2 cells and 518T2-<italic>Tubb5<sup>T238A</sup></italic> cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_0007" id="gr6" position="float"/></fig><p>Simultaneous to our efforts to develop probe reagents for biochemical
target identification studies, we utilized a forward genetics target
identification strategy that we recently reported.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Deletion of the DNA mismatch repair protein MSH2 using
CRISPR-Cas9 is sufficient to induce hypermutation in human and murine
cancer cell lines. The increased mutation frequency facilitates the
emergence of clones that harbor compound-resistant alleles in the
target of small molecule cytotoxins. We therefore generated a barcoded
(20-nucleotide barcode) clonal mSCLC cell line (319N1-M2KO) using
a lentiviral vector encoding blasticidin resistance. We successfully
generated and validated independent barcoded clones resistant to sulfonamide <bold>27</bold>. We performed compound selections using <bold>27</bold> at five concentrations close to the lethal dose, as determined by
1 week of compound exposure (EC<sub>100</sub><sup>1wk</sup>). Following
2 weeks of compound selection, compound-resistant colonies emerged
and were expanded. To confirm <italic>in vitro</italic> resistance,
we determined the IC<sub>50</sub> for five independent 319N1-M2KO
clones (A&#x02013;E) and confirmed that all were resistant to <bold>27</bold> (IC<sub>50</sub> &#x0003e; 2-fold change, <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>D,F). Interestingly, all five clones were
cross-resistant to benzamide <bold>10</bold>, suggesting a shared
molecular target or resistance mechanism (IC<sub>50</sub> &#x0003e; 2.5-fold-change, <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>E,F). The same clones
were not cross-resistant to etoposide, suggesting that general resistance
mechanisms were not responsible for the emergence of these clones
in response to selection with sulfonamide <bold>27</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">SI Figure 6</ext-link>).</p><p>To identify recurrently mutated
genes across multiple resistant
clones, all five sulfonamide <bold>27</bold> resistant clones were
subjected to exome sequencing. We identified 22 genes mutated in five
out of five clones (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>G). Among these was a common <italic>Tubb5</italic> mutation
(712A &#x0003e; G) that resulted in a T238A (Thr &#x0003e; Ala) amino acid substitution
immediately adjacent to the Cys239. It was of interest that the T238A
mutation had previously been identified in yeast tubulin (TUB2) as
a resistance mutation to benomyl, a microtubule inhibitor that also
binds at the colchicine binding site.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup> To our knowledge,
this mutation had not been previously identified in mammalian cells,
but this nonetheless raised the possibility that T238A mediated resistance
to the benzamide and sulfonamide compound reported here.</p><p>Because
multiple recurrent mutations existed in each clone, we
sought to confirm that the T238A mutation was sufficient to confer
resistance to benzamides. We engineered the T238A mutation into 518T2
mSCLC cells using CRISPR/Cas9. After transfection with Cas9 protein-sgRNA
complexes targeting <italic>Tubb5</italic> with an oligonucleotide
repair template encoding the T238A mutation and a sham control, we
selected cells with benzamide <bold>21</bold> at 400 nM for 2 weeks.
To visualize compound resistant clones, plates were stained with crystal
violet. Emerging clones were observed under the <italic>Tubb5<sup>T238A</sup></italic> condition,
whereas no clones were visible under the control condition (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>H). Compound resistance
to analog <bold>21</bold> was confirmed in 518T2<sup><italic>Tubb5</italic><sup><italic>T238A</italic></sup></sup> cells compared to parental
518T2 cells (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>I). Thus, introduction of a single T238A mutation in <italic>Tubb5</italic> in murine SCLC cell lines was sufficient to endow resistance to
the benzamides (<bold>10</bold> and <bold>21</bold>) and arylsulfonamide <bold>27</bold>. This result established a causal relationship between
the mutation and compound resistance.</p></sec></sec><sec id="sec3"><title>Chemistry</title><p>Compounds <bold>1</bold>, <bold>7</bold>, <bold>11</bold>, <bold>12</bold>, and <bold>27</bold>&#x02013;<bold>29</bold> were commercially
available. As shown in <xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>, reaction of 4-chloro-3-nitrobenzoyl chloride with a collection
of arylpiperazines <bold>I</bold> in the presence of triethylamine
delivered benzamide analogs <bold>2</bold>&#x02013;<bold>6</bold>, <bold>8</bold>&#x02013;<bold>10</bold>, and <bold>13</bold>&#x02013;<bold>15</bold>. Analogs <bold>16</bold>&#x02013;<bold>23</bold> and <bold>26</bold> were obtained via condensation of benzoic acid derivatives <bold>II</bold> with arylpiperazines <bold>I</bold> mediated by EDC as
the dehydrating agent and DMAP as the catalyst. Benzamide analogs <bold>24</bold> and <bold>25</bold> were obtained from the corresponding
phenolic benzamide intermediates via an additional propargylation
with propargyl bromide and potassium carbonate in dimethylformamide.</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Synthesis of Benzamides</title><p id="sch1-fn1">Reagents and conditions: (a)
NEt<sub>3</sub>, THF, rt; (b) (for <bold>24</bold> and <bold>25</bold>) propargyl bromide, K2CO3, DMF; (c) EDC&#x000b7;HCl, DMAP, DMF, rt.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_0008" id="gr7" position="float"/></fig></sec><sec id="sec4"><title>Conclusions</title><p>Here, we disclosed a
multipronged approach to establish the mode
of action of benzamides with anti-cancer activity to SCLC. Through
medicinal chemistry, probe reagent development, and biochemical pull-down
methods, we established that these benzamides target &#x003b2;-tubulin
through the colchicine binding pocket using a nucleophilic aromatic
substitution to covalently modify cysteine 239. Consistent with this
mechanism of action, we demonstrated that these cytotoxins impair
microtubule dynamics <italic>in vitro</italic> and induce cell cycle
arrest at the G<sub>2</sub>/M transition. In addition, &#x003b2;-tubulin
isoforms (including &#x003b2;<italic><sub>3</sub></italic> tubulin)
that encode serine at position 239 exhibited intrinsic resistance
to the benzamide compounds as a result of the reduced nucleophilicity
of serine compared to cysteine. We reported a strategy to engage serine-bearing
&#x003b2;-tubulin isoforms by developing a benzaldehyde analog that
targets serine 239 through hemiacetal formation. Forward genetics
screening with a cell line harboring engineered DNA mismatch repair
deficiency identified a compound-resistant allele in threonine 238
(Thr238Ala) that was sufficient to encode resistance to anti-cancer
toxins bearing the chloronitrobenzene S<sub>N</sub>Ar warhead.</p><p>&#x003b2;-tubulin is a well-validated therapeutic target of several
classes of anti-cancer natural products and small molecules. However,
&#x003b2;-tubulin is also increasingly identified as an unwanted off-target
of small molecules purported to act on other protein targets. Here,
we demonstrated the potential of our cell-based probe competition
binding assay and expect that the disclosed benzamide probes will
prove useful in drug discovery and development to identify compounds
with the capacity, by design or not, to bind &#x003b2;-tubulin.</p></sec><sec id="sec5"><title>Experimental Section</title><sec id="sec5.1"><title>General Methods for Chemistry</title><p>Unless otherwise specified,
all commercially available reagents were used as received. Compound <bold>1</bold> was purchased from ChemBridge (#5348909). Compounds <bold>7</bold>, <bold>11</bold>, and <bold>28</bold>&#x02013;<bold>29</bold> were purchased from ChemDiv (#Y031-8281, #Y031-8282, #Y030-0278,
and #Y031-8034). Compound <bold>27</bold> was purchased from Princeton
BioMolecular Research (#OSSK_101609). Compound <bold>12</bold> was
purchased from Enamine (#Z30011284). All reactions using dried solvents
were carried out under an atmosphere of argon in flame-dried glassware
with magnetic stirring. A dry solvent was dispensed from a solvent
purification system that passes the solvent through two columns of
dry neutral alumina. Silica gel chromatographic purifications were
performed by flash chromatography with a silica gel (Sigma, grade
60, 230&#x02013;400 mesh) packed in glass columns (the eluting solvent
was determined by thin-layer chromatography, TLC), or with an Isco
Combiflash system using Redisep Rf Flash columns with size ranging
from 4 to 80 g. Analytical TLC was performed on glass plates coated
with a 0.25 mm silica gel using UV or by iodide or KMnO<sub>4</sub> staining for visualization. Routine <sup>1</sup>H and proton-decoupled <sup>13</sup>C NMR spectra were obtained on an Agilent 400 MHz NMR spectrometer.
Chemical shifts (&#x003b4;) are reported in parts per million (ppm)
from low to high field relative to the residual solvent. Multiplicities
are given as s (singlet), bs (broad singlet), d (doublet), t (triplet),
q (quartet), dd (doublet of doublets), dt (doublet of triplets), and
m (multiplet). HRMS data were obtained from the Shimadzu Center for
Advanced Analytical Chemistry (SCAAC) at U.T. Arlington. All purchased
and synthetic compounds exhibited between 95 and 99% purity as determined
by LC&#x02013;MS analysis performed on an Agilent 1290 HPLC system
using an Eclipse XDB-C18 column (4.6 &#x000d7; 150 mm, 5 &#x003bc;m; Agilent)
that was coupled to an Agilent 6130 mass spectrometer run in ESI mode
in both positive and negative ionization with a scan range of 100&#x02013;1100 <italic>m</italic>/<italic>z</italic>. Liquid chromatography was carried
out at a flow rate of 0.5 mL/min at 20 &#x000b0;C with a 5 &#x003bc;L injection
volume using the gradient elution with aqueous acetonitrile containing
0.1% formic acid. The gradient was adjusted based on the different
polarities of different compounds.</p></sec><sec id="sec5.2"><title>General Procedure A for
the Preparation of Benzamides from 4-Chloro-3-nitrobenzoyl
Chloride and Arylpiperazines <bold>I</bold></title><p>A solution of
4-chloro-3-nitrobenzoyl chloride, arylpiperazine <bold>I</bold>, and
triethylamine in THF was stirred at room temperature for 16 h. The
concentration of the reaction mixture followed by flash chromatography
(gradient of 0&#x02013;50% EtOAc in hexane) gave the corresponding
benzamide.</p></sec><sec id="sec5.3"><title>General Procedure B for the Preparation of
Benzamides from Substituted
Benzoic Acids <bold>II</bold> and Arylpiperazines <bold>I</bold></title><p>To a solution of arylpiperazine <bold>I</bold>, benzoic acid derivative <bold>II</bold>, and DMAP in DMF was added EDC&#x000b7;HCl at rt. The resulting
reaction mixture was stirred for 16 h. Flash chromatography (gradient
of 0&#x02013;40% EtOAc in hexane) gave the corresponding benzamide.</p></sec><sec id="sec5.4"><title>(4-Chloro-3-nitrophenyl)(4-(2-chlorophenyl)piperazin-1-yl)methanone
(<bold>2</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (75.0 mg, 0.34 mmol), 1-(2-chlorophenyl)piperazine
HCl salt (104.0 mg, 0.44 mmol), and Et<sub>3</sub>N (0.90 mL, 6.45
mmol) in THF (4 mL). Yield 89 mg (68%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.97 (d, <italic>J</italic> = 1.6 Hz, 1H), 7.66&#x02013;7.55 (m, 2H), 7.36 (dd, <italic>J</italic> = 8.2, 1.5 Hz, 1H), 7.26&#x02013;7.16 (m, 1H), 7.05&#x02013;6.96
(m, 2H), 3.94 (bs, 2H), 3.60 (bs, 2H), 3.22&#x02013;2.92 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.8, 148.3, 147.7,
135.5, 132.3, 131.8, 130.75, 128.9, 128.51, 127.79, 124.66, 124.57,
120.62, 51.58, 50.92, 48.15, 42.7; HRMS calculated for C<sub>17</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 380.0563, found 380.0541.</p></sec><sec id="sec5.5"><title>(4-Chloro-3-nitrophenyl)(4-(3-methoxyphenyl)piperazin-1-yl)methanone
(<bold>3</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (106.0 mg, 0.48 mmol), 1-(3-methoxyphenyl)piperazine
(251.0 mg, 1.31 mmol), and Et<sub>3</sub>N (0.30 mL, 2.15 mmol) in
THF (4 mL). Yield 146 mg (80%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.94 (d, <italic>J</italic> = 1.7 Hz, 1H), 7.64&#x02013;7.55 (m, 2H), 7.17 (t, <italic>J</italic> = 8.0 Hz, 1H), 6.56&#x02013;6.47 (m, 1H), 6.47&#x02013;6.41 (m, 2H),
3.88 (s, 2H), 3.76 (s, 3H), 3.57 (d, <italic>J</italic> = 8.9 Hz,
2H), 3.32&#x02013;3.01 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.65, 160.6, 152.0, 147.7, 135.3, 132.3, 131.9,
130.0, 128.5, 124.7, 109.4, 105.5, 103.3, 55.2, 49.7, 49.3, 47.6,
42.4; HRMS calculated for C<sub>18</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 376.1059, found 376.1042.</p></sec><sec id="sec5.6"><title>(4-Chloro-3-nitrophenyl)(4-(<italic>m</italic>-tolyl)piperazin-1-yl)methanone
(<bold>4</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (75.0 mg, 0.34 mmol), 1-(3-methylphenyl)piperazine
(124.0 mg, 0.70 mmol), and Et<sub>3</sub>N (0.30 mL, 2.15 mmol) in
THF (4 mL). Yield 110 mg (89%) as light-yellow gummy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.97 (d, <italic>J</italic> = 1.7 Hz, 1H), 7.66&#x02013;7.57 (m, 2H), 7.17 (t, <italic>J</italic> = 7.9 Hz, 1H), 6.78&#x02013;6.70 (m, 3H), 3.91 (bs, 2H), 3.58 (bs,
2H), 3.19 (m, 4H), 2.33 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.7, 150.7, 147.8, 139.1, 135.4, 132.3, 131.9,
129.15, 128.6, 124.7, 121.85, 117.75, 114.0, 49.9, 47.8, 42.5, 21.75;
HRMS calculated for C<sub>18</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 360.1109, found 360.1090.</p></sec><sec id="sec5.7"><title>(4-Chloro-3-nitrophenyl)(4-(2,5-dimethylphenyl)piperazin-1-yl)methanone
(<bold>5</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (75.0 mg, 0.34 mmol), 1-(2,5-dimethylphenyl)piperazine
(122.0 mg, 0.64 mmol), and Et<sub>3</sub>N (0.60 mL, 4.30 mmol) in
THF (4 mL). Yield 122 mg (96%) as a light-yellow thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.99 (d, <italic>J</italic> = 1.5 Hz, 1H), 7.63 (d, <italic>J</italic> = 1.2 Hz, 2H), 7.09 (d, <italic>J</italic> = 7.6 Hz, 1H), 6.88&#x02013;6.79 (m, 2H), 4.04&#x02013;3.81
(m, 2H), 3.59 (bs, 2H), 3.03&#x02013;2.82 (m, 4H), 2.31 (s, 3H), 2.28
(s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.8,
150.35, 147.8, 136.4, 135.6, 132.3, 131.9, 131.1, 129.4, 128.45, 124.7,
124.65, 120.1, 52.1, 51.7, 48.5, 43.05, 21.2, 17.4; HRMS calculated
for C<sub>19</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>3</sub> [M +
H]<sup>+</sup> 374.1266, found 374.1242.</p></sec><sec id="sec5.8"><title>(4-(3-Bromophenyl)piperazin-1-yl)(4-chloro-3-nitrophenyl)methanone
(<bold>6</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (49.0 mg, 0.22 mmol), 1-(3-bromophenyl)piperazine
(55.0 mg, 0.23 mmol), and Et<sub>3</sub>N (0.10 mL, 0.72 mmol) in
THF (2 mL). Yield 81 mg (92%) as a white solid. <sup>1</sup>H NMR
(400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.96 (d, <italic>J</italic> =
1.8 Hz, 1H), 7.66&#x02013;7.56 (m, 2H), 7.12 (t, <italic>J</italic> = 8.0 Hz, 1H), 7.06&#x02013;6.98 (m, 2H), 6.82 (ddd, <italic>J</italic> = 8.3, 2.3, 1.0 Hz, 1H), 3.74 (m, 9 Hz, 4H), 3.38&#x02013;3.03 (m,
4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.7,
151.8, 147.8, 135.1, 132.4, 131.8, 130.6, 128.7, 124.7, 123.5, 123.3,
119.55, 115.2, 49.2, 47.5, 42.3; HRMS calculated for C<sub>17</sub>H<sub>15</sub>BrClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 424.0058,
found 424.0030.</p></sec><sec id="sec5.9"><title>3-(4-(4-Chloro-3-nitrobenzoyl)piperazin-1-yl)benzonitrile
(<bold>8</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl
chloride (100.0 mg, 0.45 mmol), 1-(3-cyanophenyl)piperazine (172.0
mg, 0.92 mmol), and Et<sub>3</sub>N (0.3 mL, 2.15 mmol) in THF (4
mL). Yield 135 mg (80%) as a light-yellow gummy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.94 (t, <italic>J</italic> = 1.2 Hz, 1H), 7.59 (d, <italic>J</italic> = 1.5 Hz, 2H), 7.37&#x02013;7.26
(m, 1H), 7.14&#x02013;7.05 (m, 3H), 4.08&#x02013;3.47 (m, 4H), 3.22
(bs, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.7,
150.7, 147.7, 135.1, 132.4, 131.9, 130.15, 128.6, 124.7, 123.55, 120.6,
119.1, 119.05, 113.0, 48.6, 47.3, 42.1; HRMS calculated for C<sub>18</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 371.0905, found 371.0882.</p></sec><sec id="sec5.10"><title>(4-Chloro-3-nitrophenyl)(4-(2,5-dichlorophenyl)piperazin-1-yl)methanone
(<bold>9</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (65.0 mg, 0.30 mmol), 1-(2,5-dichlorophenyl)piperazine
(103.0 mg, 0.34 mmol), and Et<sub>3</sub>N (0.30 mL, 2.20 mmol) in
THF (3 mL). Yield 26 mg (21%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.97 (d, <italic>J</italic> = 1.8 Hz, 1H), 7.67&#x02013;7.57 (m, 2H), 7.30 (d, <italic>J</italic> = 8.4 Hz, 1H), 7.05&#x02013;6.95 (m, 2H), 3.95 (bs, 2H), 3.61 (bs,
2H), 3.25&#x02013;2.91 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.9, 149.3, 147.9, 135.4, 133.4, 132.5, 131.9,
131.6, 128.8, 127.3, 124.75, 124.6, 121.2, 51.5, 50.9, 48.1, 42.7;
HRMS calculated for C<sub>17</sub>H<sub>15</sub>C<sub>l3</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 414.0174, found 414.0155.</p></sec><sec id="sec5.11"><title>(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(4-chloro-3-nitrophenyl)methanone
(<bold>10</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (77.0 mg, 0.35 mmol), 1-(5-chloro-2-methylphenyl)piperazine
(121.0 mg, 0.57 mmol), and Et<sub>3</sub>N (0.30 mL, 2.15 mmol) in
THF (4 mL). Yield 140 mg (68%) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.96 (d, <italic>J</italic> = 1.6 Hz, 1H), 7.61 (d, <italic>J</italic> = 2.0 Hz, 2H), 7.09 (d, <italic>J</italic> = 8.0 Hz, 1H), 7.02&#x02013;6.90 (m, 2H), 3.90 (bs, 2H),
3.57 (bs, 2H), 3.10&#x02013;2.71 (m, 4H), 2.26 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.8, 151.5, 147.7, 135.4,
132.3, 132.2, 131.85, 131.8, 131.0, 128.5, 124.6, 123.9, 119.8, 51.7,
51.5, 48.2, 42.8, 17.4; HRMS calculated for C<sub>18</sub>H<sub>17</sub>C<sub>l2</sub>N<sub>3</sub>O<sub>3</sub> [M + Na]<sup>+</sup> 416.0539,
found 416.0512.</p></sec><sec id="sec5.12"><title>(4-Chloro-3-nitrophenyl)(4-(2,4-difluorophenyl)piperazin-1-yl)methanone
(<bold>13</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (75.0 mg, 0.34 mmol), 1-(2,4-difluorophenyl)piperazine
(111.0 mg, 0.56 mmol), and Et<sub>3</sub>N (0.60 mL, 4.30 mmol) in
THF (4 mL). Yield 92 mg (71%) as a light-yellow gummy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.95 (d, <italic>J</italic> = 1.7 Hz, 1H), 7.68&#x02013;7.55 (m, 2H), 6.89 (td, <italic>J</italic> = 9.9, 9.4, 5.7 Hz, 1H), 6.80 (dtt, <italic>J</italic> = 8.1, 5.1, 3.0 Hz, 2H), 3.92 (bs, 2H), 3.59 (bs, 2H), 3.03 (m,
4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, including <sup>19</sup>F-coupling peaks) &#x003b4; 166.7, 159.7, 159.6, 157.2, 157.1,
157.1, 156.95, 154.6, 154.5, 147.75, 135.8, 135.8, 135.75, 135.7,
135.3, 132.3, 131.8, 128.6, 124.6, 120.2, 120.1, 120.1, 120.0, 111.1,
111.03, 110.85, 110.8, 105.2, 104.92, 104.91, 104.7, 51.3, 50.6, 47.95,
42.55; HRMS calculated for C<sub>17</sub>H<sub>14</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 382.0765, found 382.0742.</p></sec><sec id="sec5.13"><title>(4-Chloro-3-nitrophenyl)(4-(2,4-dimethylphenyl)piperazin-1-yl)methanone
(<bold>14</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (76 mg, 0.34 mmol), 1-(2,4-dimethylphenyl)piperazine
(122.0 mg, 0.64 mmol), and Et<sub>3</sub>N (0.30 mL, 2.15 mmol) in
THF (4 mL). Yield 120 mg (93%) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.99 (t, <italic>J</italic> = 1.2 Hz, 1H), 7.63 (d, <italic>J</italic> = 1.3 Hz, 2H), 7.03 (d, <italic>J</italic> = 2.2 Hz, 1H), 6.99 (dd, <italic>J</italic> = 8.1, 2.1
Hz, 1H), 6.91 (d, <italic>J</italic> = 8.1 Hz, 1H), 3.92 (bs, 2H),
3.71&#x02013;3.42 (m, 2H), 2.91 (m, 4H), 2.30 (s, 3H), 2.29 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.75, 148.1,
147.8, 135.6, 133.6, 132.6, 132.3, 132.0, 131.9, 128.45, 127.2, 124.7,
119.2, 52.25, 51.7, 48.5, 43.1, 20.7, 17.65; HRMS calculated for C<sub>19</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 374.1266, found 374.1241.</p></sec><sec id="sec5.14"><title>(4-Chloro-3-nitrophenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methanone
(<bold>15</bold>)</title><p>Prepared according to Procedure A using
4-chloro-3-nitrobenzoyl chloride (75.0 mg, 0.34 mmol), 1-(4-methoxyphenyl)piperazine
(120.0 mg, 0.62 mmol), and Et<sub>3</sub>N (0.60 mL, 4.30 mmol) in
THF (4 mL). Yield 65 mg (51%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.96 (d, <italic>J</italic> = 1.8 Hz, 1H), 7.68&#x02013;7.54 (m, 2H), 6.89 (d, <italic>J</italic> = 9.2 Hz, 2H), 6.84 (d, <italic>J</italic> = 9.0 Hz, 2H), 4.03&#x02013;3.80
(m, 2H), 3.76 (s, 3H), 3.57 (bs, 2H), 3.07 (m, 4H); <sup>13</sup>C
NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.65, 154.6, 147.75, 144.9,
135.4, 132.3, 131.8, 128.6, 124.6, 119.1, 114.55, 55.5, 51.3, 50.9,
47.9, 42.6; HRMS calculated for C<sub>18</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 376.1059, found 376.1045.</p></sec><sec id="sec5.15"><title>(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(4-chloro-2-nitrophenyl)methanone
(<bold>16</bold>)</title><p>Prepared according to Procedure B using
1-(5-chloro-2-methylphenyl)piperazine (61.0 mg, 0.29 mmol), 4-chloro-2-nitrobenzoic
acid (93.0 mg, 0.46 mmol), DMAP (8.0 mg, 0.07 mmol), and EDC&#x000b7;HCl
(143.0 mg, 0.75 mmol) in DMF (1 mL). Yield 62 mg (54%) as a colorless
thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 8.21
(d, <italic>J</italic> = 2.1 Hz, 1H), 7.72 (dd, <italic>J</italic> = 8.1, 2.1 Hz, 1H), 7.41 (d, <italic>J</italic> = 8.1 Hz, 1H), 7.12
(d, <italic>J</italic> = 8.0 Hz, 1H), 7.05&#x02013;6.91 (m, 2H), 3.97
(s, 2H), 3.38 (t, <italic>J</italic> = 5.0 Hz, 2H), 3.14&#x02013;2.75
(m, 4H), 2.28 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 165.62, 151.7, 146.0, 135.9, 134.6, 132.1, 131.9, 131.1,
131.05, 129.3, 125.1, 123.85, 119.9, 51.3, 51.2, 47.3, 42.4, 17.4;
HRMS calculated for C<sub>18</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.0722, found 394.0720.</p></sec><sec id="sec5.16"><title>(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(2-chloro-3-nitrophenyl)methanone
(<bold>17</bold>)</title><p>Prepared according to Procedure B using
1-(5-chloro-2-methylphenyl)piperazine (53.0 mg, 0.25 mmol), 2-chloro-3-nitrobenzoic
acid (102.0 mg, 0.50 mmol), DMAP (3.0 mg, 0.03 mmol), and EDC&#x000b7;HCl
(114.0 mg, 0.59 mmol) in DMF (1.5 mL). Yield 45 mg (45%) as a colorless
thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.79
(dd, <italic>J</italic> = 7.6, 2.1 Hz, 1H), 7.51&#x02013;7.40 (m, 2H),
7.03 (d, <italic>J</italic> = 8.1 Hz, 1H), 6.91 (dd, <italic>J</italic> = 8.1, 2.1 Hz, 1H), 6.87 (d, <italic>J</italic> = 2.1 Hz, 1H), 4.00&#x02013;3.81
(m, 2H), 3.44&#x02013;3.21 (m, 2H), 3.00&#x02013;2.68 (m, 4H), 2.19
(s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 164.9,
151.6, 148.7, 138.8, 132.2, 131.9, 131.1, 131.0, 128.2, 125.7, 123.9,
123.3, 119.8, 51.8, 51.5, 47.2, 42.3, 17.4; HRMS calculated for C<sub>18</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M
+ Na]<sup>+</sup> 416.0539, found 416.0513.</p></sec><sec id="sec5.17"><title>(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(3-chloro-5-nitrophenyl)methanone
(<bold>18</bold>)</title><p>Prepared according to Procedure B using
1-(5-chloro-2-methylphenyl)piperazine (57.0 mg, 0.27 mmol), 3-chloro-5-nitrobenzoic
acid (103.0 mg, 0.51 mmol), DMAP (3.0 mg, 0.03 mmol), and EDC&#x000b7;HCl
(115.0 mg, 0.60 mmol) in DMF (1.5 mL). Yield 92 mg (86%) as a colorless
thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 8.19
(t, <italic>J</italic> = 2.0 Hz, 1H), 8.10 (dd, <italic>J</italic> = 2.1, 1.4 Hz, 1H), 7.69 (t, <italic>J</italic> = 1.7 Hz, 1H), 7.03
(d, <italic>J</italic> = 8.0 Hz, 1H), 6.95&#x02013;6.84 (m, 2H), 3.85
(s, 2H), 3.49 (s, 2H), 2.85 (d, <italic>J</italic> = 27.0 Hz, 4H),
2.19 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4;
166.4, 151.5, 148.6, 138.6, 136.1, 133.2, 132.2, 131.9, 131.0, 124.85,
124.0, 120.4, 119.9, 51.8, 51.5, 48.2, 42.9, 17.4; HRMS calculated
for C<sub>18</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.0722, found 394.0671.</p></sec><sec id="sec5.18"><title>(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(3-chloro-4-nitrophenyl)methanone
(<bold>19</bold>)</title><p>Prepared according to Procedure B using
1-(5-chloro-2-methylphenyl)piperazine (58.0 mg, 0.27 mmol), 3-chloro-4-nitrobenzoic
acid (103.0 mg, 0.51 mmol), DMAP (3.0 mg, 0.03 mmol), and EDC&#x000b7;HCl
(115.0 mg, 0.60 mmol) in DMF (1.5 mL). Yield 96 mg (90%) as a colorless
thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.92
(d, <italic>J</italic> = 8.2 Hz, 1H), 7.62 (d, <italic>J</italic> =
1.7 Hz, 1H), 7.46 (dd, <italic>J</italic> = 8.3, 1.7 Hz, 1H), 7.10
(d, <italic>J</italic> = 8.1 Hz, 1H), 6.98 (dd, <italic>J</italic> = 8.0, 2.1 Hz, 1H), 6.94 (s, 1H), 3.91 (s, 2H), 3.53 (s, 2H), 2.91
(d, <italic>J</italic> = 40.9 Hz, 4H), 2.26 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.7, 151.5, 148.2, 140.7,
132.2, 131.85, 131.0, 130.55, 127.7, 126.2, 125.95, 123.9, 119.8,
51.9, 51.45, 48.1, 42.7, 17.4; HRMS calculated for C<sub>18</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.0720, found 394.0701.</p></sec><sec id="sec5.19"><title>(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(4-fluoro-3-nitrophenyl)methanone
(<bold>20</bold>)</title><p>Prepared according to Procedure B using
1-(5-chloro-2-methylphenyl)piperazine (52.0 mg, 0.25 mmol), 4-fluoro-3-nitrobenzoic
acid (75.0 mg, 0.40 mmol), DMAP (3.0 mg, 0.025 mmol), and EDC&#x000b7;HCl
(100.0 mg, 0.52 mmol) in DMF (1.5 mL). Yield 77 mg (83%) as a colorless
thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 8.19
(dd, <italic>J</italic> = 7.0, 2.2 Hz, 1H), 7.78 (ddd, <italic>J</italic> = 8.6, 4.2, 2.2 Hz, 1H), 7.40 (dd, <italic>J</italic> = 10.4, 8.5
Hz, 1H), 7.12 (d, <italic>J</italic> = 8.1 Hz, 1H), 7.05&#x02013;6.91
(m, 2H), 3.77 (m, 6 Hz, 4H), 3.12&#x02013;2.73 (m, 4H), 2.29 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, including <sup>19</sup>F-coupling peaks) &#x003b4; 166.9, 157.4, 154.7, 151.6, 137.2, 137.1,
134.6, 134.5, 132.6, 132.5, 132.2, 132.1, 131.9, 131.05, 125.4, 125.4,
123.9, 119.9, 119.8, 119.1, 118.9, 51.7, 51.6, 51.4, 48.3, 43.0, 17.4;
HRMS calculated for C<sub>18</sub>H<sub>17</sub>ClFN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 378.1015, found 378.0985.</p></sec><sec id="sec5.20"><title>(4-Bromo-3-nitrophenyl)(4-(5-chloro-2-methylphenyl)piperazin-1-yl)methanone
(<bold>21</bold>)</title><p>Prepared according to Procedure B using
1-(5-chloro-2-methylphenyl)piperazine (59.0 mg, 0.28 mmol), 4-bromo-3-nitrobenzoic
acid (105.0 mg, 0.43 mmol), DMAP (3.0 mg, 0.03 mmol), and EDC&#x000b7;HCl
(100.0 mg, 0.52 mmol) in DMF (1.5 mL). Yield 115 mg (93%) as a colorless
thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.94
(d, <italic>J</italic> = 2.0 Hz, 1H), 7.82 (d, <italic>J</italic> =
8.2 Hz, 1H), 7.53 (dd, <italic>J</italic> = 8.2, 2.0 Hz, 1H), 7.12
(d, <italic>J</italic> = 8.1 Hz, 1H), 7.04&#x02013;6.92 (m, 2H), 4.04&#x02013;3.46
(m, 4H), 2.92 (bs, 4H), 2.28 (s, 3H); <sup>13</sup>C NMR (101 MHz,
CDCl<sub>3</sub>) &#x003b4; 166.9, 151.6, 149.7, 136.1, 135.5, 132.2,
131.9, 131.75, 131.05, 124.5, 123.9, 119.9, 116.0, 51.7, 48.2, 42.9,
17.4; HRMS calculated for C<sub>18</sub>H<sub>17</sub>BrClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 438.0215, found 438.0190.</p></sec><sec id="sec5.21"><title>(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(4-iodo-3-nitrophenyl)methanone
(<bold>22</bold>)</title><p>Prepared according to Procedure B using
1-(5-chloro-2-methylphenyl)piperazine (55.0 mg, 0.26 mmol), 4-iodo-3-nitrobenzoic
acid (143.0 mg, 0.49 mmol), DMAP (3.0 mg, 0.03 mmol), and EDC&#x000b7;HCl
(100.0 mg, 0.52 mmol) in DMF (1.5 mL). Yield 115 mg (91%) as a colorless
thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 8.03
(d, <italic>J</italic> = 8.1 Hz, 1H), 7.85 (d, <italic>J</italic> =
1.9 Hz, 1H), 7.27 (dd, <italic>J</italic> = 8.1, 2.0 Hz, 1H), 7.02
(d, <italic>J</italic> = 8.0 Hz, 1H), 6.96&#x02013;6.84 (m, 2H), 4.02&#x02013;3.18
(m, 3H), 2.85 (m, 5H), 2.19 (s, 3H); <sup>13</sup>C NMR (101 MHz,
CDCl<sub>3</sub>) &#x003b4; 167.0, 152.9, 151.6, 142.4, 136.9, 132.2,
131.9, 131.8, 131.05, 124.2, 123.9, 119.9, 88.0, 51.7, 48.2, 42.8,
17.4; HRMS calculated for C<sub>18</sub>H<sub>17</sub>ClIN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 486.0084, found 486.0076.</p></sec><sec id="sec5.22"><title>(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(3-nitro-4-(trifluoromethoxy)phenyl)methan-one
(<bold>23</bold>)</title><p>Prepared according to Procedure B using
1-(5-chloro-2-methylphenyl)piperazine (51.0 mg, 0.24 mmol), 3-nitro-4-(trifluoromethoxy)benzoic
acid (51.0 mg, 0.20 mmol), DMAP (4.0 mg, 0.03 mmol), and EDC&#x000b7;HCl
(47.0 mg, 0.24 mmol) in DMF (1 mL). Yield 54 mg (60%) as a colorless
thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 8.00
(d, <italic>J</italic> = 2.1 Hz, 1H), 7.69 (dd, <italic>J</italic> = 8.5, 2.1 Hz, 1H), 7.46 (dq, <italic>J</italic> = 8.6, 1.5 Hz,
1H), 7.04 (d, <italic>J</italic> = 8.0 Hz, 1H), 6.97&#x02013;6.86 (m,
2H), 4.00&#x02013;3.38 (m, 4H), 2.84 (m, 4H), 2.20 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 166.5, 151.5, 142.4, 142.0,
142.0, 135.3, 133.0, 132.2, 131.9, 131.0, 125.05, 124.0, 123.38, 123.37,
121.4, 119.9, 118.8, 51.55, 48.3, 47.25, 42.9, 17.42, 17.36; HRMS
calculated for C<sub>19</sub>H<sub>17</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 444.0932, found 444.0920.</p></sec><sec id="sec5.23"><title>(4-Chloro-3-nitrophenyl)(4-(3-(prop-2-yn-1-yloxy)phenyl)piperazin-1-yl)methanone
(<bold>24</bold>)</title><p>Intermediate (4-chloro-3-nitrophenyl)(4-(3-hydroxyphenyl)piperazin-1-yl)methanone
was prepared according to Procedure A using 4-chloro-3-nitrobenzoyl
chloride (1.05 g, 4.75 mmol), 1-(3-hydroxyphenyl)piperazine (1.30
g, 7.29 mmol), and Et<sub>3</sub>N (4 mL, 28.69 mmol) in THF (20 mL).
The reaction mixture was diluted with EtOAc (50 mL) and washed with
H<sub>2</sub>O (3 &#x000d7; 50 mL) and brine (50 mL). The collected organics
were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced
pressure to give (4-chloro-3-nitrophenyl)(4-(3-hydroxyphenyl)piperazin-1-yl)methanone
as a light-yellow solid. Without further purification, (4-chloro-3-nitrophenyl)(4-(3-hydroxyphenyl)piperazin-1-yl)methanone
(180.0 mg, 0.49 mmol) was dissolved in DMF (5 mL). After addition
of K<sub>2</sub>CO<sub>3</sub> (500.0 mg, 3.62 mmol) and propargyl
bromide (80% in PhMe, 0.25 mL, 2.24 mmol), the resulting mixture was
stirred at room temperature for 16 h. The reaction mixture was diluted
with CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and quenched with H<sub>2</sub>O (20 mL). The organic layer was washed with H<sub>2</sub>O (3 &#x000d7; 20 mL) and brine (20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. The residue was
purified by flash chromatography (gradient of 0&#x02013;50% EtOAc in
hexane) to yield 97 mg (49%) of <bold>24</bold> as a brown gummy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.96 (d, <italic>J</italic> = 1.8 Hz, 1H), 7.71&#x02013;7.47 (m, 2H), 7.19 (ddd, <italic>J</italic> = 8.4, 7.2, 1.5 Hz, 1H), 6.64&#x02013;6.28 (m, 3H), 4.66
(d, <italic>J</italic> = 2.4 Hz, 2H), 3.73 (m, 4H), 3.19 (m, 4H),
2.52 (t, <italic>J</italic> = 2.4 Hz, 1H); <sup>13</sup>C NMR (101
MHz, CDCl<sub>3</sub>) &#x003b4; 166.7, 158.6, 152.0, 147.8, 135.3,
132.3, 131.85, 130.0, 128.6, 124.7, 110.2, 106.25, 104.2, 78.6, 75.6,
55.8, 49.6, 47.6, 42.35; HRMS calculated for C<sub>20</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 400.1059, found
400.1056.</p></sec><sec id="sec5.24"><title>(4-Methyl-3-nitrophenyl)(4-(3-(prop-2-yn-1-yloxy)phenyl)piperazin-1-yl)methanone
(<bold>25</bold>)</title><p>Intermediate (4-(3-hydroxyphenyl)piperazin-1-yl)(4-methyl-3-nitrophenyl)methanone
was prepared according to Procedure B using 4-methyl-3-nitrobenzoic
acid (500.0 mg, 2.76 mmol), 1-(3-hydroxyphenyl)piperazine (740.0 mg,
4.14 mmol), DMAP (34.0 mg, 0.27 mmol), and EDC&#x000b7;HCl (800.0 mg,
4.14 mmol) in DMF (5 mL). The reaction mixture was diluted with EtOAc
(40 mL) and washed with H<sub>2</sub>O (3 &#x000d7; 40 mL) and brine
(40 mL). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure to yield crude (4-(3-hydroxyphenyl)piperazin-1-yl)(4-methyl-3-nitrophenyl)methanone
as a light-yellow solid. Without further purification, crude (4-(3-hydroxyphenyl)piperazin-1-yl)(4-methyl-3-nitrophenyl)methanone
(71.0 mg, 0.50 mmol) was dissolved in DMF (1.5 mL). After addition
of K<sub>2</sub>CO<sub>3</sub> (207.0 mg, 1.50 mmol) and propargyl
bromide (80% in PhMe, 150 &#x025a1;L, 1.20 mmol), the mixture was stirred
at room temperature for 16 h. The reaction mixture was diluted with
CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and quenched with H<sub>2</sub>O (20 mL). The organic layer was washed with H<sub>2</sub>O (3 &#x000d7;
20 mL) and brine (20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and
concentrated under reduced pressure. The residue was purified by flash
chromatography (gradient of 0&#x02013;50% EtOAc in hexane) to yield
35 mg (71%) of <bold>25</bold> as a colorless thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.98 (d, <italic>J</italic> = 1.7 Hz, 1H), 7.52 (dd, <italic>J</italic> = 7.8, 1.7 Hz, 1H),
7.36 (d, <italic>J</italic> = 7.8 Hz, 1H), 7.13 (t, <italic>J</italic> = 8.5 Hz, 1H), 6.55&#x02013;6.41 (m, 3H), 4.60 (d, <italic>J</italic> = 2.4 Hz, 2H), 3.68 (m, 4H), 3.14 (bs, 4H), 2.57 (s, 3H), 2.45 (t, <italic>J</italic> = 2.4 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 167.8, 158.65, 152.1, 149.0, 135.4, 134.55, 133.25, 131.6,
130.0, 123.7, 110.2, 106.25, 104.2, 78.6, 75.5, 55.8, 49.5, 47.6,
42.3, 20.4; HRMS calculated for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 380.1605, found 380.1604.</p></sec><sec id="sec5.25"><title>4-(4-(3,5-Dimethoxyphenyl)piperazine-1-carbonyl)-2-nitrobenzaldehyde
(<bold>26</bold>)</title><p>Prepared according to Procedure B using
1-(3,5-dimethoxyphenyl)piperazine (130.0 mg, 0.58 mmol), 4-formyl-3-nitrobenzoic
acid (125.0 mg), DMAP (6.0 mg, 0.05 mmol), and EDC&#x000b7;HCl (200.0
mg, 1.04 mmol) in DMF (1 mL). Yield 57 mg as a colorless thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 10.35 (s, 1H), 8.10
(d, <italic>J</italic> = 1.5 Hz, 1H), 7.93 (d, <italic>J</italic> =
7.8 Hz, 1H), 7.75 (dd, <italic>J</italic> = 7.8, 1.5 Hz, 1H), 6.00
(s, 3H), 4.01&#x02013;3.76 (m, 2H), 3.70 (s, 6H), 3.49 (d, <italic>J</italic> = 19.3 Hz, 2H), 3.14 (d, <italic>J</italic> = 53.0 Hz,
4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 187.3,
166.5, 161.6, 152.55, 149.5, 141.0, 132.4, 131.9, 130.2, 123.5, 95.88,
92.6, 55.3, 49.8, 49.4, 47.5, 42.3; HRMS calculated for C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 400.1503,
found 400.1501.</p></sec><sec id="sec5.26"><title>Cytotoxicity Assay</title><p>Mouse SCLC cell
lines were seeded
in duplicate in 96-well plates, 10,000 cells and 200 &#x003bc;L of DMEM
media (5% FBS) per well. After overnight incubation, compounds were
dispensed using a D300e Digital Dispenser (TECAN) in 10-point dose
response manner using <inline-formula id="d31e2715"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_m001.gif"/></inline-formula> log dilutions. Cell
viability was assessed
after 72 h using CellTiter-Glo luminescent cell viability assay (Promega,
#G7571). The CellTiter-Glo reagent was diluted by adding PBS/Triton-X
(1%) (1:1 ratio). Each value was normalized to cells treated with
DMSO, and the IC<sub>50</sub> values were calculated using GraphPad
Prism software.</p></sec><sec id="sec5.27"><title>Cross-Linking Experiments</title><p>Murine
SCLC cells, 518T2,
were plated in 12-well plates (1 million cells per well) in 1 mL of
DMEM media (5% FBS) per well. The following day, probe <bold>24</bold> or probe <bold>25</bold> dissolved in DMSO was dispensed at increasing
concentrations (50 nM to 50 &#x003bc;M). After 1.5 h incubation at 37
&#x000b0;C in 5% CO<sub>2</sub>, cells were washed gently with PBS and
lysed in 1% SDS Buffer A (50 mM HEPES, pH 7.4, 10 mM KCl, 2 mM MgCl<sub>2</sub>), freshly supplemented with 1:10,000 benzonase (Sigma-Aldrich).
For competition experiments, analogs dissolved in DMSO were dispensed
at increasing concentrations (100 nM to 50 &#x003bc;M) first and murine
SCLC cells, 518T2, were plated in 12-well plates (1 million cells
per well) in 1 mL DMEM media (5% FBS) per well. The following day,
either probe <bold>24</bold> or probe <bold>25</bold> was dispensed
in DMSO at increasing concentrations (50 nM to 50 &#x003bc;M). After
1.5 h incubation at 37 &#x000b0;C in 5% CO<sub>2</sub>, cells were washed
gently with PBS and lysed in 1% SDS Buffer A (50 mM HEPES, pH 7.4,
10 mM KCl, 2 mM MgCl<sub>2</sub>), freshly supplemented with 1:10,000
benzonase (Sigma-Aldrich). Click chemistry was performed as previously
described.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup></p></sec><sec id="sec5.28"><title>Protein Purification</title><p>For purification experiments,
cells were plated in 15 cm dishes at a large scale to obtain 100 mg
of protein per condition and allowed to adhere overnight. The following
day, cells were subjected to photocross-linking experiments described
above. Instead of 25 &#x003bc;M Alexa Fluor 532 azide, 100 &#x003bc;M
diazo biotin azide (Click Chemistry Tools, #1041) was used for the
click reaction. Proteins were precipitated with four volumes of acetone
cooled to &#x02212;80 &#x000b0;C, and the insoluble protein pellets were
centrifuged at 6000<italic>g</italic> and then resolubilized in PBS
(4% SDS) overnight. The insoluble material was pelleted by centrifugation
at 20,000<italic>g</italic>, and the soluble supernatant was filtered
using 0.45 &#x003bc;m and 0.22 &#x003bc;m filters. Streptavidin agarose
beads (Solu-link) were added and incubated with the resolubilized
protein for 1 h at 25 &#x000b0;C. Beads were washed three times with
4% SDS in PBS, and the protein was eluted at 95 &#x000b0;C in Laemmli
sample buffer. Proteins were resolved by SDS-PAGE, and the gel was
stained with silver stain (Pierce, #24612). For proteomics analysis,
samples were run until proteins enter into the SDS-PAGE gel, and each
sample was cut and sent for shotgun analysis using LC&#x02013;MS/MS.</p></sec><sec id="sec5.29"><title>Proteomics Analysis</title><p>Gel band samples were digested
overnight with trypsin (Pierce) following reduction and alkylation
with DTT and iodoacetamide (Sigma-Aldrich). The samples then underwent
solid-phase extraction cleanup with an Oasis HLB plate (Waters), and
the resulting samples were injected onto an Orbitrap Fusion Lumos
mass spectrometer coupled to an Ultimate 3000 RSLC-Nano liquid chromatography
system. Samples were injected onto a 75 &#x003bc;m i.d., 75 cm-long
EasySpray column (Thermo) and eluted with a gradient from 0 to 28%
buffer B over 90 min. Buffer A contained 2% (v/v) ACN and 0.1% formic
acid in water, and buffer B contained 80% (v/v) ACN, 10% (v/v) trifluoroethanol,
and 0.1% formic acid in water. The mass spectrometer was operated
in positive ion mode with a source voltage of 1.5 kV and an ion transfer
tube temperature of 275 &#x000b0;C. MS scans were acquired at 120,000
resolution in the Orbitrap, and up to 10 MS/MS spectra were obtained
in the ion trap for each full spectrum acquired using higher-energy
collisional dissociation (HCD) for ions with charges 2&#x02013;7. Dynamic
exclusion was set for 25 s after an ion was selected for fragmentation.</p><p>Raw MS data files were analyzed using Proteome Discoverer v2.4
SP1 (Thermo), with peptide identification performed using Sequest
HT searching against the human protein database from UniProt. Fragment
and precursor tolerances of 10 ppm and 0.6 Da were specified, respectively,
and three missed cleavages were allowed. Carbamidomethylation of Cys
was set as a fixed modification, with oxidation of Met set as a variable
modification. The false-discovery rate cutoff was 1% for all peptides.</p><p>Proteomic data for samples <bold>24</bold> and <bold>25</bold> are
accessible at MassIVE accession number: MSV000085897 (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ftp://massive.ucsd.edu/MSV000085897/">ftp://massive.ucsd.edu/MSV000085897/</uri>).</p></sec><sec id="sec5.30"><title>Expression and Purification of &#x003b2;<sub>3</sub> Human &#x003b1;&#x003b2;-Tubulin</title><p>Human &#x003b1;&#x003b2;-tubulin (non-tagged TUBA1B gene and TUBB3
gene with a cleavable His-tag at the C-terminus) was expressed in
insect cells as described previously.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> Briefly, Tni cells (Expression Systems) and ESF-921 insect cell
medium (Expression Systems) were used for expression. Cells were harvested
approximately &#x0223c;42 h post-infection, re-suspended in 3 volumes
of lysis buffer (25 mM Hepes, pH 7.4, 30 mM imidazole, 1 mM MgSO<sub>4</sub>, 50 &#x003bc;M GTP), and lysed using a glass dounce. Lysate
was clarified by centrifugation, and recombinant tubulin was purified
by Ni-affinity (5 mL Ni-NTA column, TaKaRA) and anion exchange (4
mL Source-Q column, GE Amersham) chromatography. The His-tag was removed
by TEV protease (2 h on ice using a TEV at 0.2 mg/mL final concentration)
prior to anion exchange chromatography. Peak fractions were pooled,
concentrated to 15&#x02013;20 &#x003bc;M, buffer-exchanged to BRB80 with
50 &#x003bc;M GTP, flash-frozen on liquid nitrogen in 100 &#x003bc;L aliquots,
and stored at &#x02212;80 &#x000b0;C.</p></sec><sec id="sec5.31"><title>Microtubule Dynamics Assays</title><p>Microtubule dynamics were
measured by time-lapse differential interference contrast microscopy,
as described previously.<sup><xref ref-type="bibr" rid="ref30">30</xref>&#x02212;<xref ref-type="bibr" rid="ref32">32</xref></sup> Temperature was maintained at
30 &#x000b0;C using an enclosure fit to the microscope body, and the
microscope was controlled using a MicroManager.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Briefly, assays were performed in flow chambers using GMPCPP
seeds made from brain tubulin (5% biotinylated; PurSolutions) attached
to coverslips using neutravidin (Invitrogen). Microtubule dynamics
were measured in the following buffer (144 mM PIPES, pH 6.9, 3.6 mM
MgCl2, 50 mM KCl, 1 mM GTP, 0.1 mg/mL BSA, 0.07% methylcellulose,
and 4% DMSO final concentration). DMSO was the solvent where compounds
were dissolved in. We used a higher than typical concentration of
PIPES because microtubule dynamics were not robustly observable at
lower concentrations for the recombinant human tubulin. Images were
acquired every 50 ms (using a Photometrics Prime95B camera) and averaged
in batches of 30 to improve signal to noise. Recordings typically
lasted for 30 min. Microtubule growing rates were obtained from kymographs
prepared using ImageJ.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></p></sec></sec></body><back><notes id="notes2" notes-type="si"><title>Supporting Information Available</title><p>The Supporting
Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01482?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01482</ext-link>.<list id="silist" list-type="simple"><list-item><p>List of proteins by mass
spectrometry analysis in tubulin-probe
purification with analog <bold>24</bold> compared to compound <bold>25</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Somatic mutations identified in resistant clones to
compound <bold>27</bold> compared to parental 319N1-M2KO cells (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_002.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Supplementary
tables (benzamide analogs and proteins
enriched), supplementary figures (dose&#x02013;response curves, SDS-PAGE
full gel images, and kymographs), methods (Selection of Resistant
Clones; <italic>Tubb5<sup>T238A</sup></italic> Point Mutation; Whole
Exome Sequence Analysis; and Identification of Recurrently Mutated
Genes in Sulfonamide <bold>27</bold>-Resistant Clones), and copies
of <sup>1</sup>H and <sup>13</sup>C spectra, HPLC chromatograms and
HRMS data (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_003.pdf">PDF</ext-link>)</p></list-item><list-item><p>Molecular formula strings (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.0c01482/suppl_file/jm0c01482_si_004.csv">CSV</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_si_001.xlsx"><caption><p>jm0c01482_si_001.xlsx</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile2"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_si_002.xlsx"><caption><p>jm0c01482_si_002.xlsx</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile3"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_si_003.pdf"><caption><p>jm0c01482_si_003.pdf</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile4"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm0c01482_si_004.csv"><caption><p>jm0c01482_si_004.csv</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes1"><title>Author Contributions</title><p><sup>&#x02207;</sup> J.M.P. and R.R. contributed equally to this
work</p></notes><notes notes-type="" id="notes3"><title>Author Contributions</title><p>All authors
have given approval to the final version of the manuscript.</p></notes><notes notes-type="COI-statement" id="NOTES-d7e2960-autogenerated"><p>The authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>This work was funded through a UT Southwestern Dean&#x02019;s
Circle of Friends Pilot Synergy Grant. J.K.D.B. acknowledges support
from the Welch Foundation (Grant I-1422) and holds the Julie and Louis
Beecherl, Jr., Chair in Medical Science. D.G.M. acknowledges support
from the Welch Foundation (Grant I-2040), the Disease Oriented Scholars
Program at UT Southwestern, a Clinical Investigator Award from the
Damon Runyon Cancer Research Foundation (102-19), the Cancer Prevention
and Research Institute of Texas (RR140084 and RP190141), and the National
Cancer Institute of the NIH (U54CA231649). J.M.P. is supported by
a fellowship from the Chilton Family Foundation. HRMS data were obtained
from the Shimadzu Center for Advanced Analytical Chemistry (SCAAC)
at UT Arlington. Work in the laboratory of L.M.R. was supported by
the NIH (R01-GM098543) and the Welch Foundation (Grant I-1908). Andrew
Lemoff and colleagues at the UT Southwestern Medical Center Proteomics
Core Facility performed mass spectrometry analysis on benzamide-bound
proteins. We thank John Minna and Adi Gazdar for sharing human SCLC
cell lines. We thank Deepak Nijhawan for critically reading the manuscript
and for numerous helpful discussions. We thank Kuanqing Liu for critically
reading the manuscript.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>McFadden</surname><given-names>D. G.</given-names></name>; <name><surname>Papagiannakopoulos</surname><given-names>T.</given-names></name>; <name><surname>Taylor-Weiner</surname><given-names>A.</given-names></name>; <name><surname>Stewart</surname><given-names>C.</given-names></name>; <name><surname>Carter</surname><given-names>S. L.</given-names></name>; <name><surname>Cibulskis</surname><given-names>K.</given-names></name>; <name><surname>Bhutkar</surname><given-names>A.</given-names></name>; <name><surname>McKenna</surname><given-names>A.</given-names></name>; <name><surname>Dooley</surname><given-names>A.</given-names></name>; <name><surname>Vernon</surname><given-names>A.</given-names></name>; <name><surname>Sougnez</surname><given-names>C.</given-names></name>; <name><surname>Malstrom</surname><given-names>S.</given-names></name>; <name><surname>Heimann</surname><given-names>M.</given-names></name>; <name><surname>Park</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>F.</given-names></name>; <name><surname>Farago</surname><given-names>A. F.</given-names></name>; <name><surname>Dayton</surname><given-names>T.</given-names></name>; <name><surname>Shefler</surname><given-names>E.</given-names></name>; <name><surname>Gabriel</surname><given-names>S.</given-names></name>; <name><surname>Getz</surname><given-names>G.</given-names></name>; <name><surname>Jacks</surname><given-names>T.</given-names></name>
<article-title>Genetic and
clonal dissection of murine small cell lung carcinoma progression
by genome sequencing</article-title>. <source>Cell</source>
<year>2014</year>, <volume>156</volume>, <fpage>1298</fpage>&#x02013;<lpage>1311</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.02.031</pub-id>.<pub-id pub-id-type="pmid">24630729</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Calbo</surname><given-names>J.</given-names></name>; <name><surname>Meuwissen</surname><given-names>R.</given-names></name>; <name><surname>van Montfort</surname><given-names>E.</given-names></name>; <name><surname>van Tellingen</surname><given-names>O.</given-names></name>; <name><surname>Berns</surname><given-names>A.</given-names></name>
<article-title>Genotype-phenotype relationships
in a mouse model for human small-cell
lung cancer</article-title>. <source>Cold Spring Harbor Symp. Quant.
Biol.</source>
<year>2005</year>, <volume>70</volume>, <fpage>225</fpage>&#x02013;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1101/sqb.2005.70.026</pub-id>.<pub-id pub-id-type="pmid">16869758</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Gazdar</surname><given-names>A. F.</given-names></name>; <name><surname>Savage</surname><given-names>T. K.</given-names></name>; <name><surname>Johnson</surname><given-names>J. E.</given-names></name>; <name><surname>Berns</surname><given-names>A.</given-names></name>; <name><surname>Sage</surname><given-names>J.</given-names></name>; <name><surname>Linnoila</surname><given-names>R. I.</given-names></name>; <name><surname>MacPherson</surname><given-names>D.</given-names></name>; <name><surname>McFadden</surname><given-names>D. G.</given-names></name>; <name><surname>Farago</surname><given-names>A.</given-names></name>; <name><surname>Jacks</surname><given-names>T.</given-names></name>; <name><surname>Travis</surname><given-names>W. D.</given-names></name>; <name><surname>Brambilla</surname><given-names>E.</given-names></name>
<article-title>The comparative
pathology of genetically engineered mouse models for neuroendocrine
carcinomas of the lung</article-title>. <source>J Thorac Oncol</source>
<year>2015</year>, <volume>10</volume>, <fpage>553</fpage>&#x02013;<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1097/JTO.0000000000000459</pub-id>.<pub-id pub-id-type="pmid">25675280</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Meuwissen</surname><given-names>R.</given-names></name>; <name><surname>Linn</surname><given-names>S. C.</given-names></name>; <name><surname>Linnoila</surname><given-names>R. I.</given-names></name>; <name><surname>Zevenhoven</surname><given-names>J.</given-names></name>; <name><surname>Mooi</surname><given-names>W. J.</given-names></name>; <name><surname>Berns</surname><given-names>A.</given-names></name>
<article-title>Induction of small
cell lung cancer
by somatic inactivation of both Trp53 and Rb1 in a conditional mouse
model</article-title>. <source>Cancer Cell</source>
<year>2003</year>, <volume>4</volume>, <fpage>181</fpage>&#x02013;<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1016/S1535-6108(03)00220-4</pub-id>.<pub-id pub-id-type="pmid">14522252</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Nile</surname><given-names>A. H.</given-names></name>; <name><surname>Tripathi</surname><given-names>A.</given-names></name>; <name><surname>Yuan</surname><given-names>P.</given-names></name>; <name><surname>Mousley</surname><given-names>C. J.</given-names></name>; <name><surname>Suresh</surname><given-names>S.</given-names></name>; <name><surname>Wallace</surname><given-names>I. M.</given-names></name>; <name><surname>Shah</surname><given-names>S. D.</given-names></name>; <name><surname>Pohlhaus</surname><given-names>D. T.</given-names></name>; <name><surname>Temple</surname><given-names>B.</given-names></name>; <name><surname>Nislow</surname><given-names>C.</given-names></name>; <name><surname>Giaever</surname><given-names>G.</given-names></name>; <name><surname>Tropsha</surname><given-names>A.</given-names></name>; <name><surname>Davis</surname><given-names>R. W.</given-names></name>; <name><surname>St Onge</surname><given-names>R. P.</given-names></name>; <name><surname>Bankaitis</surname><given-names>V. A.</given-names></name>
<article-title>PITPs as
targets for selectively
interfering with phosphoinositide signaling in cells</article-title>. <source>Nat. Chem. Biol.</source>
<year>2014</year>, <volume>10</volume>, <fpage>76</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1389</pub-id>.<pub-id pub-id-type="pmid">24292071</pub-id></mixed-citation></ref><ref id="ref6"><note><p>The trifluoromethoxy group
has been described
as a leaving group in S<sub>N</sub>Ar, see:</p></note><mixed-citation publication-type="journal" id="cit6"><name><surname>Marrec</surname><given-names>O.</given-names></name>; <name><surname>Billard</surname><given-names>T.</given-names></name>; <name><surname>Vors</surname><given-names>J.-P.</given-names></name>; <name><surname>Pazenok</surname><given-names>S.</given-names></name>; <name><surname>Langlois</surname><given-names>B. R.</given-names></name>
<article-title>A New and direct trifluoromethoxylation
of aliphatic substrates with 2,4-dinitro(trifluoromethoxy)benzene</article-title>. <source>Adv. Synth. Catal.</source>
<year>2010</year>, <volume>352</volume>, <fpage>2831</fpage>&#x02013;<lpage>2837</lpage>. <pub-id pub-id-type="doi">10.1002/adsc.201000488</pub-id>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Theodoropoulos</surname><given-names>P. C.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Budhipramono</surname><given-names>A.</given-names></name>; <name><surname>Thompson</surname><given-names>B. M.</given-names></name>; <name><surname>Madhusudhan</surname><given-names>N.</given-names></name>; <name><surname>Mitsche</surname><given-names>M. A.</given-names></name>; <name><surname>McDonald</surname><given-names>J. G.</given-names></name>; <name><surname>De Brabander</surname><given-names>J. K.</given-names></name>; <name><surname>Nijhawan</surname><given-names>D.</given-names></name>
<article-title>A medicinal chemistry-driven approach identified the
sterol isomerase EBP as the molecular target of TASIN colorectal cancer
toxins</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2020</year>, <volume>142</volume>, <fpage>6128</fpage>&#x02013;<lpage>6138</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b13407</pub-id>.<pub-id pub-id-type="pmid">32163279</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Speers</surname><given-names>A. E.</given-names></name>; <name><surname>Cravatt</surname><given-names>B. F.</given-names></name>
<article-title>Profiling enzyme activities in vivo using click chemistry
methods</article-title>. <source>Chem. Biol.</source>
<year>2004</year>, <volume>11</volume>, <fpage>535</fpage>&#x02013;<lpage>546</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2004.03.012</pub-id>.<pub-id pub-id-type="pmid">15123248</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Wright</surname><given-names>A. T.</given-names></name>; <name><surname>Cravatt</surname><given-names>B. F.</given-names></name>
<article-title>Chemical proteomic
probes for profiling cytochrome
p450 activities and drug interactions in vivo</article-title>. <source>Chem. Biol.</source>
<year>2007</year>, <volume>14</volume>, <fpage>1043</fpage>&#x02013;<lpage>1051</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2007.08.008</pub-id>.<pub-id pub-id-type="pmid">17884636</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Lee</surname><given-names>G.</given-names></name>; <name><surname>Elwood</surname><given-names>F.</given-names></name>; <name><surname>McNally</surname><given-names>J.</given-names></name>; <name><surname>Weiszmann</surname><given-names>J.</given-names></name>; <name><surname>Lindstrom</surname><given-names>M.</given-names></name>; <name><surname>Amaral</surname><given-names>K.</given-names></name>; <name><surname>Nakamura</surname><given-names>M.</given-names></name>; <name><surname>Miao</surname><given-names>S.</given-names></name>; <name><surname>Cao</surname><given-names>P.</given-names></name>; <name><surname>Learned</surname><given-names>R. M.</given-names></name>; <name><surname>Chen</surname><given-names>J. L.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>
<article-title>T0070907, a selective
ligand for peroxisome proliferator-activated receptor gamma, functions
as an antagonist of biochemical and cellular activities</article-title>. <source>J Biol Chem</source>
<year>2002</year>, <volume>277</volume>, <fpage>19649</fpage>&#x02013;<lpage>19657</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M200743200</pub-id>.<pub-id pub-id-type="pmid">11877444</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Harris</surname><given-names>G.</given-names></name>; <name><surname>Schaefer</surname><given-names>K. L.</given-names></name>
<article-title>The microtubule-targeting
agent T0070907 induces proteasomal
degradation of tubulin</article-title>. <source>Biochem. Biophys. Res.
Commun.</source>
<year>2009</year>, <volume>388</volume>, <fpage>345</fpage>&#x02013;<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2009.08.009</pub-id>.<pub-id pub-id-type="pmid">19665001</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Schaefer</surname><given-names>K. L.</given-names></name>; <name><surname>Takahashi</surname><given-names>H.</given-names></name>; <name><surname>Morales</surname><given-names>V. M.</given-names></name>; <name><surname>Harris</surname><given-names>G.</given-names></name>; <name><surname>Barton</surname><given-names>S.</given-names></name>; <name><surname>Osawa</surname><given-names>E.</given-names></name>; <name><surname>Nakajima</surname><given-names>A.</given-names></name>; <name><surname>Saubermann</surname><given-names>L. J.</given-names></name>
<article-title>PPARgamma
inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta
and proteasome-independent mechanism, resulting in cell cycle arrest,
apoptosis and reduced metastasis of colorectal carcinoma cells</article-title>. <source>Int. J. Cancer</source>
<year>2007</year>, <volume>120</volume>, <fpage>702</fpage>&#x02013;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.22361</pub-id>.<pub-id pub-id-type="pmid">17096328</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Yan</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Qiu</surname><given-names>Q.</given-names></name>; <name><surname>Ye</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>
<article-title>Covalent modification
of Cys-239 in &#x003b2;-tubulin by small molecules
as a strategy to promote tubulin heterodimer degradation</article-title>. <source>J Biol Chem</source>
<year>2019</year>, <volume>294</volume>, <fpage>8161</fpage>&#x02013;<lpage>8170</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA118.006325</pub-id>.<pub-id pub-id-type="pmid">30940730</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Frankmoelle</surname><given-names>W. P.</given-names></name>; <name><surname>Medina</surname><given-names>J. C.</given-names></name>; <name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Narbut</surname><given-names>M. R.</given-names></name>; <name><surname>Beckmann</surname><given-names>H.</given-names></name>
<article-title>Glutathione
S-transferase metabolism of the antineoplastic pentafluorophenylsulfonamide
in tissue culture and mice</article-title>. <source>Drug Metab. Dispos.</source>
<year>2000</year>, <volume>28</volume>, <fpage>951</fpage>&#x02013;<lpage>958</lpage>.<pub-id pub-id-type="pmid">10901706</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Medina</surname><given-names>J. C.</given-names></name>; <name><surname>Santha</surname><given-names>E.</given-names></name>; <name><surname>Frankmoelle</surname><given-names>W. P.</given-names></name>; <name><surname>Chou</surname><given-names>T.-C.</given-names></name>; <name><surname>Learned</surname><given-names>R. M.</given-names></name>; <name><surname>Narbut</surname><given-names>M. R.</given-names></name>; <name><surname>Stott</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>P.</given-names></name>; <name><surname>Jaen</surname><given-names>J. C.</given-names></name>; <name><surname>Rosen</surname><given-names>T.</given-names></name>; <name><surname>Timmermans</surname><given-names>P. B. M. W. M.</given-names></name>; <name><surname>Beckmann</surname><given-names>H.</given-names></name>
<article-title>Selective, covalent
modification of &#x003b2;-tubulin
residue Cys-239 by T138067, an antitumor agent with in vivo efficacy
against multidrug-resistant tumors</article-title>. <source>Proc. Natl.
Acad. Sci. U. S. A.</source>
<year>1999</year>, <volume>96</volume>, <fpage>5686</fpage>&#x02013;<lpage>5691</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.96.10.5686</pub-id>.<pub-id pub-id-type="pmid">10318945</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Bai</surname><given-names>R.</given-names></name>; <name><surname>Covell</surname><given-names>D. G.</given-names></name>; <name><surname>Pei</surname><given-names>X.-F.</given-names></name>; <name><surname>Ewell</surname><given-names>J. B.</given-names></name>; <name><surname>Nguyen</surname><given-names>N. Y.</given-names></name>; <name><surname>Brossi</surname><given-names>A.</given-names></name>; <name><surname>Hamel</surname><given-names>E.</given-names></name>
<article-title>Mapping the
binding site of colchicinoids
on &#x003b2;-tubulin. 2-Chloroacetyl-2-demethylthiocolchicine covalently
reacts predominantly with cysteine 239 and secondarily with cysteine
354</article-title>. <source>J Biol Chem</source>
<year>2000</year>, <volume>275</volume>, <fpage>40443</fpage>&#x02013;<lpage>40452</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M005299200</pub-id>.<pub-id pub-id-type="pmid">11005811</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Steinmetz</surname><given-names>M. O.</given-names></name>; <name><surname>Prota</surname><given-names>A. E.</given-names></name>
<article-title>Microtubule-targeting agents: strategies to hijack
the cytoskeleton</article-title>. <source>Trends Cell Biol</source>
<year>2018</year>, <volume>28</volume>, <fpage>776</fpage>&#x02013;<lpage>792</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2018.05.001</pub-id>.<pub-id pub-id-type="pmid">29871823</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Brouhard</surname><given-names>G. J.</given-names></name>; <name><surname>Rice</surname><given-names>L. M.</given-names></name>
<article-title>Microtubule dynamics: an interplay
of biochemistry
and mechanics</article-title>. <source>Nat Rev Mol Cell Biol</source>
<year>2018</year>, <volume>19</volume>, <fpage>451</fpage>&#x02013;<lpage>463</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-018-0009-y</pub-id>.<pub-id pub-id-type="pmid">29674711</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Dumontet</surname><given-names>C.</given-names></name>; <name><surname>Jordan</surname><given-names>M. A.</given-names></name>
<article-title>Microtubule-binding
agents: a dynamic field of cancer
therapeutics</article-title>. <source>Nat Rev Drug Discov</source>
<year>2010</year>, <volume>9</volume>, <fpage>790</fpage>&#x02013;<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3253</pub-id>.<pub-id pub-id-type="pmid">20885410</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Ferlini</surname><given-names>C.</given-names></name>; <name><surname>Raspaglio</surname><given-names>G.</given-names></name>; <name><surname>Mozzetti</surname><given-names>S.</given-names></name>; <name><surname>Cicchillitti</surname><given-names>L.</given-names></name>; <name><surname>Filippetti</surname><given-names>F.</given-names></name>; <name><surname>Gallo</surname><given-names>D.</given-names></name>; <name><surname>Fattorusso</surname><given-names>C.</given-names></name>; <name><surname>Campiani</surname><given-names>G.</given-names></name>; <name><surname>Scambia</surname><given-names>G.</given-names></name>
<article-title>The seco-taxane IDN5390 is able to
target class III &#x003b2;-tubulin and to overcome paclitaxel resistance</article-title>. <source>Cancer Res.</source>
<year>2005</year>, <volume>65</volume>, <fpage>2397</fpage>&#x02013;<lpage>2405</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3065</pub-id>.<pub-id pub-id-type="pmid">15781655</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Mozzetti</surname><given-names>S.</given-names></name>; <name><surname>Ferlini</surname><given-names>C.</given-names></name>; <name><surname>Concolino</surname><given-names>P.</given-names></name>; <name><surname>Filippetti</surname><given-names>F.</given-names></name>; <name><surname>Raspaglio</surname><given-names>G.</given-names></name>; <name><surname>Prislei</surname><given-names>S.</given-names></name>; <name><surname>Gallo</surname><given-names>D.</given-names></name>; <name><surname>Martinelli</surname><given-names>E.</given-names></name>; <name><surname>Ranelletti</surname><given-names>F. O.</given-names></name>; <name><surname>Ferrandina</surname><given-names>G.</given-names></name>; <name><surname>Scambia</surname><given-names>G.</given-names></name>
<article-title>Class III &#x003b2;-tubulin
overexpression is a prominent mechanism of paclitaxel resistance in
ovarian cancer patients</article-title>. <source>Clin Cancer Res</source>
<year>2005</year>, <volume>11</volume>, <fpage>298</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">15671559</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Arnst</surname><given-names>K. E.</given-names></name>; <name><surname>Banerjee</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Deng</surname><given-names>S.</given-names></name>; <name><surname>Hwang</surname><given-names>D. J.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Miller</surname><given-names>D. D.</given-names></name>
<article-title>Current
advances of tubulin inhibitors as dual acting
small molecules for cancer therapy</article-title>. <source>Med. Res.
Rev.</source>
<year>2019</year>, <volume>39</volume>, <fpage>1398</fpage>&#x02013;<lpage>1426</lpage>. <pub-id pub-id-type="doi">10.1002/med.21568</pub-id>.<pub-id pub-id-type="pmid">30746734</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Ye</surname><given-names>X.</given-names></name>; <name><surname>Kim</surname><given-names>T.</given-names></name>; <name><surname>Geyer</surname><given-names>E. A.</given-names></name>; <name><surname>Rice</surname><given-names>L. M.</given-names></name>
<article-title>Insights into allosteric control
of microtubule dynamics from a buried &#x003b2;-tubulin mutation that
causes faster growth and slower shrinkage</article-title>. <source>Protein
Sci.</source>
<year>2020</year>, <volume>29</volume>, <fpage>1429</fpage>&#x02013;<lpage>1439</lpage>. <pub-id pub-id-type="doi">10.1002/pro.3842</pub-id>.<pub-id pub-id-type="pmid">32077153</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Jost</surname><given-names>M.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Gilbert</surname><given-names>L. A.</given-names></name>; <name><surname>Horlbeck</surname><given-names>M. A.</given-names></name>; <name><surname>Krenning</surname><given-names>L.</given-names></name>; <name><surname>Menchon</surname><given-names>G.</given-names></name>; <name><surname>Rai</surname><given-names>A.</given-names></name>; <name><surname>Cho</surname><given-names>M. Y.</given-names></name>; <name><surname>Stern</surname><given-names>J. J.</given-names></name>; <name><surname>Prota</surname><given-names>A. E.</given-names></name>; <name><surname>Kampmann</surname><given-names>M.</given-names></name>; <name><surname>Akhmanova</surname><given-names>A.</given-names></name>; <name><surname>Steinmetz</surname><given-names>M. O.</given-names></name>; <name><surname>Tanenbaum</surname><given-names>M. E.</given-names></name>; <name><surname>Weissman</surname><given-names>J. S.</given-names></name>
<article-title>Combined CRISPRi/a-based
chemical genetic screens reveal that rigosertib is a microtubule-destabilizing
agent</article-title>. <source>Mol. Cell</source>
<year>2017</year>, <volume>68</volume>, <fpage>210</fpage>&#x02013;<lpage>223.e6</lpage>. <comment>e6</comment><pub-id pub-id-type="doi">10.1016/j.molcel.2017.09.012</pub-id>.<pub-id pub-id-type="pmid">28985505</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Yan</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Niu</surname><given-names>L.</given-names></name>; <name><surname>Ye</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>
<article-title>The natural
compound withaferin A covalently binds to Cys239 of &#x003b2;-tubulin
to promote tubulin degradation</article-title>. <source>Mol. Pharmacol.</source>
<year>2019</year>, <volume>96</volume>, <fpage>711</fpage>&#x02013;<lpage>719</lpage>. <pub-id pub-id-type="doi">10.1124/mol.119.117812</pub-id>.<pub-id pub-id-type="pmid">31585985</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Povedano</surname><given-names>J. M.</given-names></name>; <name><surname>Liou</surname><given-names>J.</given-names></name>; <name><surname>Wei</surname><given-names>D.</given-names></name>; <name><surname>Srivatsav</surname><given-names>A.</given-names></name>; <name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Xie</surname><given-names>Y.</given-names></name>; <name><surname>McFadden</surname><given-names>D. G.</given-names></name>
<article-title>Engineering forward genetics into
cultured cancer cells for chemical target identification</article-title>. <source>Cell Chem. Biol.</source>
<year>2019</year>, <fpage>1315</fpage>&#x02013;<lpage>1321.e3</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2019.06.006</pub-id>.<pub-id pub-id-type="pmid">31303577</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Machin</surname><given-names>N. A.</given-names></name>; <name><surname>Lee</surname><given-names>J. M.</given-names></name>; <name><surname>Barnes</surname><given-names>G.</given-names></name>
<article-title>Microtubule
stability in budding
yeast: characterization and dosage suppression of a benomyl-dependent
tubulin mutant</article-title>. <source>Mol. Biol. Cell</source>
<year>1995</year>, <volume>6</volume>, <fpage>1241</fpage>&#x02013;<lpage>1259</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.6.9.1241</pub-id>.<pub-id pub-id-type="pmid">8534919</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Thomas</surname><given-names>J. H.</given-names></name>; <name><surname>Neff</surname><given-names>N. F.</given-names></name>; <name><surname>Botstein</surname><given-names>D.</given-names></name>
<article-title>Isolation and characterization
of
mutations in the &#x003b2;-tubulin gene of Saccharomyces cerevisiae</article-title>. <source>Genetics</source>
<year>1985</year>, <volume>111</volume>, <fpage>715</fpage>&#x02013;<lpage>734</lpage>.<pub-id pub-id-type="pmid">2998923</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Madhusudhan</surname><given-names>N.</given-names></name>; <name><surname>Hu</surname><given-names>B.</given-names></name>; <name><surname>Mishra</surname><given-names>P.</given-names></name>; <name><surname>Calva-Moreno</surname><given-names>J. F.</given-names></name>; <name><surname>Patel</surname><given-names>K.</given-names></name>; <name><surname>Boriack</surname><given-names>R.</given-names></name>; <name><surname>Ready</surname><given-names>J. M.</given-names></name>; <name><surname>Nijhawan</surname><given-names>D.</given-names></name>
<article-title>Target discovery of selective non-small-cell
lung cancer toxins reveals inhibitors of mitochondrial complex I</article-title>. <source>ACS Chem. Biol.</source>
<year>2020</year>, <volume>15</volume>, <fpage>158</fpage>&#x02013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.9b00734</pub-id>.<pub-id pub-id-type="pmid">31874028</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Geyer</surname><given-names>E. A.</given-names></name>; <name><surname>Burns</surname><given-names>A.</given-names></name>; <name><surname>Lalonde</surname><given-names>B. A.</given-names></name>; <name><surname>Ye</surname><given-names>X.</given-names></name>; <name><surname>Piedra</surname><given-names>F. A.</given-names></name>; <name><surname>Huffaker</surname><given-names>T. C.</given-names></name>; <name><surname>Rice</surname><given-names>L. M.</given-names></name>
<article-title>A mutation uncouples
the tubulin
conformational and GTPase cycles, revealing allosteric control of
microtubule dynamics</article-title>. <source>Elife</source>
<year>2015</year>, <volume>4</volume>, <elocation-id>e10113</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10113</pub-id>.<pub-id pub-id-type="pmid">26439009</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Kim</surname><given-names>T.</given-names></name>; <name><surname>Rice</surname><given-names>L. M.</given-names></name>
<article-title>Long-range, through-lattice coupling improves predictions
of microtubule catastrophe</article-title>. <source>Mol. Biol. Cell</source>
<year>2019</year>, <volume>30</volume>, <fpage>1451</fpage>&#x02013;<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E18-10-0641</pub-id>.<pub-id pub-id-type="pmid">30943103</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Majumdar</surname><given-names>S.</given-names></name>; <name><surname>Kim</surname><given-names>T.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Munyoki</surname><given-names>S.</given-names></name>; <name><surname>Tso</surname><given-names>S. C.</given-names></name>; <name><surname>Brautigam</surname><given-names>C. A.</given-names></name>; <name><surname>Rice</surname><given-names>L. M.</given-names></name>
<article-title>An isolated CLASP
TOG domain suppresses microtubule
catastrophe and promotes rescue</article-title>. <source>Mol. Biol.
Cell</source>
<year>2018</year>, <volume>29</volume>, <fpage>1359</fpage>&#x02013;<lpage>1375</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E17-12-0748</pub-id>.<pub-id pub-id-type="pmid">29851564</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Edelstein</surname><given-names>A.</given-names></name>; <name><surname>Amodaj</surname><given-names>N.</given-names></name>; <name><surname>Hoover</surname><given-names>K.</given-names></name>; <name><surname>Vale</surname><given-names>R.</given-names></name>; <name><surname>Stuurman</surname><given-names>N.</given-names></name>
<article-title>Computer control
of microscopes using &#x003bc;Manager</article-title>. <source>Curr Protoc
Mol Biol</source>
<year>2010</year>, <volume>92</volume>, <fpage>14.20.1</fpage>&#x02013;<lpage>14.20.17</lpage>. <pub-id pub-id-type="doi">10.1002/0471142727.mb1420s92</pub-id>.</mixed-citation></ref></ref-list></back></article>